[{"article": "\"Nothing happens,\" he told Stahl.\nIt was that relentlessness of leukemia that had given Kanzius the idea to build his radio wave machine in the first place.\nSo he wondered: if he injected a cancerous tumor with some kind of metal, would radio waves heat up the metal and cook the cancer cells to death, and only the cancer cells?\nBut Kanzius wasn't happy with all the time it would take Curley to get through the usual human clinical trials and approval by the FDA.\nWhat he did have was a deadly form of leukemia and a determination to use whatever time he had left to come up with a better way to treat the disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n \nThis story stumbles badly by portraying the Kanzius device as revolutionary, when it is actually just one of many applications of well-known principles and techniques for treating cancer. For example, radiofrequency ablation (the technical term for the Kanzius approach) is already used to treat tumors in the liver and elsewhere when conventional surgery isn\u2019t a good option. Indeed, searching www.pubmed.gov for studies of radiofrequency ablation of cancer yields almost 3,000 citations. \nThe added technique of using molecules that preferentially bind to cancerous cells in order to concentrate metallic nanoparticles within tumors is common to many targeted cancer treatments.\n The story ignored vast swaths of current cancer research and treatment.", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have put this study into the larger context of cash payments for health incentives. This has been demonstrated to work on a number of fronts, including encouraging mothers to give birth in health centers, discouraging risky sex, and smoking cessation.", "answer": 0}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\nCanadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\n\u201cThese patients were referred for colonoscopy, most commonly due to symptoms,\u201d Lieberman said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that colonoscopy is the dominant screening for colon cancer.", "answer": 1}, {"article": "MRI has long been known as an effective breast cancer screening modality that offers better sensitivity than mammography and ultrasound.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nThe results also highlight the ability of MRI in the detection of more aggressive types of cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release establishes that the novelty of the study lies in its challenge of the conventional wisdom that supplemental MRI screening should be recommended\u00a0to high-risk women but not average-risk women.", "answer": 1}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nBut it will be some years before that approach is proven -- or not.\nBut most insurers won't pay for it, because they consider it experimental.\nBut specialists don't think that anymore.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story doesn\u2019t try to oversell the novelty of shockwave therapy.", "answer": 1}, {"article": "Pregnancy experts, including those at the American College of Obstetricians and Gynecologists, recommend that most pregnant women get 30 minutes of exercise a day.\nThe research in question involved mice, not women.\nThe Baylor scientists were able to correct for those variables.\nAnd that difference persisted into mouse adulthood.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the current study goes beyond available observational studies in humans by utilizing an experimental design in mice.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story overstates things when it quotes a researcher who says that Deplin represents \u201ca totally new way to look at depression.\u201d A brief search turned up a study that examined a different folic acid derivative (brand name\u00a0Leuvocorin) for treatment of resistant depression some 10 years ago. And several existing therapeutic approaches,\u00a0including\u00a0supplementation with omega-3 fatty acids and the amino acid SAM-e (S-adenosylmethionine), are based on the idea that individuals with\u00a0depression lack the building blocks needed to manufacture sufficient quantities of certain neurotransmitters.\u00a0The premise of these\u00a0approaches\u00a0is very\u00a0similar to that which is driving research on Deplin.", "answer": 0}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nTOKYO--(BUSINESS WIRE)--Hitachi, Ltd. (TSE:6501, \u201cHitachi\u201d) today announced that Johns Hopkins Medicine has selected Hitachi to provide its proton beam therapy (PBT) system at Sibley Memorial Hospital located in Washington, D.C.\nHitachi will continue to globally expand the healthcare business where proton therapy is its flagship solution, and contribute to cancer treatment around the world.\nThe proton center at Sibley Memorial Hospital will be an impressive demonstration of industry and academic medicine collaborating to bring a new technology and new cancer treatment modality to Washington, D.C. and the surrounding communities.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release fails on two fronts here. First, the news release claims, \u201cThis collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital.\u201d The fact that this a \u201cmulti-room\u201d system is not a meaningful claim when there are other facilities under construction (at least one of which will apparently open before Sibley\u2019s) nearby. Second, the release did not meet our standard for establishing the novelty of the technology. The release states, \u201cThe proton center at Sibley Memorial Hospital will be an impressive demonstration of industry and academic medicine collaborating to bring a new technology and new cancer treatment modality to Washington, D.C. and the surrounding communities.\u201d But PBT is not a new cancer treatment modality, nor will it be new to Washington D.C.\u00a0Proton therapy has been used clinically since the mid-1950s. The first proton accelerator (cyclotron) was developed in 1932 by E. O. Lawrence and S. Livingston, and Nobel physics laureate Robert Wilson proposed using it for radiation therapy in 1946. The \u201cpassive scattering\u201d technique noted in the news release was used initially at the outset. The \u201cspot scanning\u201d technique described in the release was developed and first implemented in Switzerland during the 1990s. Most proton centers can accommodate treatment using both techniques.", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that this was a new use (treatment of osteoporosis in elderly individuals who have already sustained a hip fracture) for a treatment that has FDA approval for a slightly different application.", "answer": 1}, {"article": "The information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\nMoving forward, longer term, observational studies are needed to confirm the safety of fetal exposure to tenofovir treatment, says Pan.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release just barely implies novelty with this statement which suggests a change in treating infected women who are pregnant:\n\u201cBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy. Those with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.\u201d\nWhile the drug itself isn\u2019t novel, positive outcomes from a controlled trial on pregnant women carrying the virus does seem to introduce a new treatment approach.", "answer": 1}, {"article": "\u201cOur lab is on an island in the South.\nThis information is in the early stages of transforming the category of after-sun care\u2014a category traditionally limited to aloe vera-laden moisturizers and gels that lowered the temperature of sun-parched skin but not much else.\nNot everyone is convinced of the effectiveness of after-sun care.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\nA new school of thought in the beauty world is pushing the idea that what you put on your skin after a day at the beach could play a part in reducing sun damage.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article identifies a number of after-sun products and notes that the marketing of these items is spurred in part by a research article published this year.", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\n\u201cBased on current evidence, bisphosphonates should not be used for prevention of colorectal cancer,\u201d Jacobs said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story made it clear that the findings are part of a series of findings, some of them contradictory, about the side benefits of different drugs for cancer prevention.", "answer": 1}, {"article": ".\nIn background material, the researchers stated the progestin-releasing IUD should be effective in treating AEH and also early endometrial cancer, as long as those patients were evaluated with laparoscopy, ultrasound and MRI to make sure their cancer had not spread and there was no simultaneous ovarian cancer.\nBakkum-Gomez has also used the method in her practice and is conducting a study of the IUD, which was originally designed as a contraceptive device, for this purpose.\nNine of the women in the study successfully delivered babies.\nHowever, all the women were alive and seemingly cancer-free by the end of the study after further treatment (either the IUD and GnRH treatment or a hysterectomy), the study reported.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that the Mirena IUD is not a new idea, but using it to treat early-stage endometrial cancer is relatively novel.", "answer": 1}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nBut after another 18 months, there was no such difference.\n\u201cPhysicians cannot easily ignore diagnoses made with screening tests because it is impossible for them to determine whether their patients have real disease or pseudodisease,\u201d Lauer notes.\nEven when screening helps predict health problems down the road, Lauer adds, that doesn\u2019t mean treatments are necessarily beneficial.\nSo in theory, treating them early on might help stave off some the more than 1.2 million heart attacks \u2014 a third of them fatal \u2014 that occur every year in the U.S.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the screening test could be deduced from the story.", "answer": 1}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story establish the true novelty of the approach?", "explanation": "While we were uncomfortable with this story\u2019s characterization of thermoplasty as a \"new medical breakthrough\" (for reasons discussed here), the treatment is relatively new and different from existing techniques. We don\u2019t think the story misled in this regard.\u00a0\u00a0", "answer": 1}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nSome researchers question whether symptoms could be alleviated using probiotic therapy, or \"healthy\" bacteria to restore bacterial balance in the gut.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nColic affects up to 28% of infants and has no known cause or cure.\nThe findings were published online today in Pediatrics.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story failed to mention important background here. The study reported on was actually a follow-up to a previous\u00a0open label study (the researchers knew which children were getting what treatment) conducted by these same investigators and which also found a benefit for L reuteri\u00a0on colic. The fact that this second, blinded trial has confirmed the previous\u00a0findings should increase our confidence that something real is happeneing here.\u00a0Still, as previously noted, larger, independent\u00a0studies\u00a0will be needed to\u00a0conclusively establish a benefit for probiotics on colic. \u00a0\u00a0", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nJust because the system produced strong results in mice does not mean people will respond the same way.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\nBut experts say the findings provide hope for future treatments for people.\nAnd whereas the Massachusetts researchers examined beta cells exclusively for their study, the ViaCyte team is exploring using less mature cells that, once implanted, differentiate into both insulin-producing beta cells and those that secrete another hormone called glucagon that\u2019s deficient in the disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "News stories often don\u2019t address the novelty of a treatment or research finding. But this story actually uses the word \u201cnovel,\u201d which sort of puts a spotlight on the category for us. The story quotes one of the study\u2019s funders calling the protective cell bubbles studied in the research \u201cnovel materials.\u201d We think the story actually does establish their novelty with enough context and caveats.", "answer": 1}, {"article": "Right now, the work done by Topakian's group is still \"experimental,\" he said.\nThose who would benefit from the ultrasound test are people with known carotid stenosis who are fit for surgery, Topakian said.\nWEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\nDr. Lars Marquardt,a professor of surgery at the University of Erlangen-Nuremberg in Germany and co-author of an accompanying journal editorial, said surgery for people with asymptomatic carotid steno sis is done too frequently.\nThe problem is identifying the patients at the highest risk for stroke, he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is really not clear from this story whether the 2 ultrasound techniques are new, are currently in use for other applications, are both in use for visualizing carotids but are not usually used in combination as in the study.\u00a0 Is this something new or not?", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentioned that the results of this study were not novel and built on existing research.", "answer": 1}, {"article": ".\nAccording to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily.\nThe new drug stabilizes dopamine signaling in areas of the brain that control movement and coordination.\nOne U.S. neurologist agreed that the drug seems promising against a disease with few treatment options.\nSide effects among patients taking the drug were similar to the placebo group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Pridopidine is an experimental drug candidate for Huntington\u2019s disease and has been in clinical trials for the past several years.", "answer": 1}, {"article": "It\u2019s common for people who suffer from irritable bowel syndrome (IBS) to also struggle with depression.\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression.\nThat\u2019s why Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, thinks the fMRI findings are the most interesting and important aspect of the new study: they signal that the probiotics may really be working on the brain itself.\nMost previous research on this topic has been on healthy people without mood disorders.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job of establishing where\u00a0the true novelty of the research lies, which is in the study population used (individuals without IBS and depression or anxiety).", "answer": 1}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nThe picture of selenium\u2019s health benefits \u2014 or possible health risks \u2014 has been anything but clear.\nResearchers measured participants\u2019 cholesterol levels at the beginning of the study and after six months on the selenium supplements or placebo.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story acknowledges previous research that had linked high selenium with higher cholesterol levels.", "answer": 1}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nLehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made clear that this is a relatively new experimental approach for a disc herniation.", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that the device is the first medical device for obesity approved by the FDA since 2007.", "answer": 1}, {"article": "But we don't know we're right yet.\"\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nThose efforts have failed to produce a single approved drug so far.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what appears to be novel about this drug compared with others that reduce amyloid plaques.\nOne is that the drug appears to ignore benign forms of amyloid protein while attacking the toxic forms thought to damage brain cells. Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid.\nBut while the story is clear that the new paper is presenting details of research first reported last year, it doesn\u2019t explain why the results are now \u201cremarkable\u201d whereas last year they were considered \u201cdisappointing,\u201d\u00a0\u201cmixed\u201d\u00a0and a \u201csetback.\u201d\nWe\u2019ll rate this a borderline Satisfactory.", "answer": 1}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nFor that reason, he and other experts say, most sufferers never even see an allergist.\nBecause they were not considered very sensitive, physicians were left with a lasting impression that blood testing was inferior to skin testing.\nDr. Mitchell, the Manhattan allergist, called that approach promising.\nThe blood test, which is not without its own ouch factor, measures levels of circulating IgE.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that the blood tests were developed in the 1970s but that newer tests have become available more recently.", "answer": 1}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News.\nHowever, they note, \u201cthere is no clear basis for believing that the effects of optimism on health differ by sex or race.\u201d\n\nFinally, the researchers emphasize that while some people may think they\u2019re just not optimistic, it is something that is modifiable.\n\u201cOptimism is linked with lower inflammation and healthier biomarker levels and lipid levels, so there could be an independent effect on optimism.\u201d\n\nShe said her team plans to focus more on the potential impact of optimism on biological functioning in future research.\n\u201cSo in our study we wanted to expand that and look at all-cause mortality and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d\n\nFor the study, the researchers analyzed data on from 2004 to 2012 on 70,000 women who participated in the Nurses\u2019 Health Study, a long-running research project tracking women\u2019s health via surveys every two years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0explains what\u2019s novel here is how the research looks at all-cause mortality vs specific health behaviors and outcomes. This is established with this statement:\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News. \u201cSo in our study we wanted to expand that and look at all-cause mortality\u00a0and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d", "answer": 1}, {"article": "This week, Novartis signed a deal to have Roche unit Foundation Medicine provide genomic profiling of patient samples taken from Novartis\u2019 clinical oncology trials.\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\nOther drugmakers including Roche have seen similar investigational medicines stumble, making Novartis\u2019s progress here hopeful news, doctors involved in the trial said.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\nSamit Hirawat, head of Novartis\u2019s cancer drug development, said in an interview the side-effects profile of alpelisib held up.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We learn\u2013via the lead researcher\u2013that this trial provides the \u201cmost encouraging\u201d results to date in a study looking at a PI3K inhibitor in breast cancer. That establishes novelty, but we think the story should have sought independent expert viewpoint to provide context on the limitations of the results, which were based on progression-free survival and not overall survival.\nIt does not include the information that one other PI3K inhibitor is currently on the market and used to treat a type of lymphoma.", "answer": 1}, {"article": "He is president and chair of the department of public health sciences at the University of Li\u00e8ge in Belgium.\nNearly one in 100 people have evidence of knee osteoarthritis on an X-ray.\nNov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C.\nIn people with osteoarthritis, the cartilage in a joint wears away in some areas.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Because the story explained that a form of strontium is available as a prescription drug for osteoporosis in several countries and because it is clear that the study in question is about a new use for this medication, we\u2019ll give the story the benefit of the doubt \u2013 even though it could have explained better that the idea that strontium ranelate can be effective for osteoarthritis is not entirely new. In studies of women taking the drug for osteoporosis, the drug seemed to have a beneficial effect on\u00a0markers of cartilage degradation and symptoms of spinal osteoarthritis. Those studies paved the way for the trial being reported on here, but there was no mention of that previous research.", "answer": 1}, {"article": "Animal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\nThe analysis appears online in The American Journal of Clinical Nutrition.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nAll patients were interviewed about diet, health habits and medical history.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least provided one line of context about past research in this field: \u201cAnimal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\u201d", "answer": 1}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nDr. Biesecker acknowledged that there was no guarantee of success.\nOtherwise, lots of people would have early heart disease but no obvious risk factors.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This research is certifiably novel, although other studies have looked for genetic determinants.", "answer": 1}, {"article": "Visit the American Heart Association for more on statins.\nPotluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\nWhile it did not prove a cause-and-effect connection, the study of nearly 1 million cancer patients found that those taking statin drugs such as Lipitor and Crestor appeared to have:\n\u2022 and a 30 percent lower risk of dying from colon cancer.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the novelty for this particular association of statins with decreased cancer risk. There have been a number of large meta-analyses and retrospective studies about statins and cancer risk reduction (all showing different findings), and this latest result should have been placed in context within the body of research.\nIt is implied (but not stated) that perhaps the use of 1 million patient records is the largest study searching for the correlation \u2013 but the story does not state it.", "answer": 0}, {"article": "Learn more about psoriasis treatments from the National Psoriasis Foundation.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\nOf the increased infections and cancers, Reich said, \"Although these differences were not statistically significant, they lead to questions regarding a favorable risk-benefit profile of the drug.\"\nFor people living with psoriasis, Bebo said the message from this study is that \"dramatic progress has been made from where we were just five years ago.\"\nThe study volunteers had had psoriasis for at least six months, and the condition affected at least 10 percent of their bodies.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "On this point, WebMD\u2019s version of the story was better because it at least reminded readers that \u201ca similar drug, Stelara\u2026was approved by the FDA in 2009.\u201d", "answer": 0}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that Erbitux was first used to treat colon cancer, but is now approved to treat head and neck cancer.", "answer": 1}, {"article": "\"People were saying, 'I had absolutely zero symptoms.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nIt could be that the whipworm larvae weren't prepared correctly.\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\nBack in Berkeley, Velasquez-Manoff thought he might one of the lucky ones.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty by letting us know that studies go back a few years, so it\u2019s not a new concept.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains when the first paired organ donation took place, letting readers know this is not \u201cnew,\u201d per se, although a national policy allowing widespread paired organ donation would be new. ", "answer": 1}, {"article": "Liver cancer is the second-leading primary cause of cancer-related deaths worldwide.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n(New York, NY - January 18, 2017) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better chance at survival.\nThis study tested regorafenib's effectiveness as a second-line therapy on 573 patients previously treated with sorafenib, 194 of whom were given a placebo.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that this is only the second pharmaceutical treatment for HCC proven to affect patient survival, and outlines what the study findings may mean for future research on how regorafenib may be used in treating earlier stages of HCC.", "answer": 1}, {"article": "Glenn Jaffe, M.D., a professor in the Department of Ophthalmology at Duke University School of Medicine, said adalimumab works to treat uveitis by targeting a protein that is thought to promote inflammation.\nJaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nDr. Jaffe served as a consultant for AbbVie, and other study authors also report financial relationships with the company.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty is somewhat nuanced, but explained well enough: Uveitis is a bag full of symptoms, and the damage involved can span across the entire eye. By measuring how it affected the most frequent symptoms, \u201cthe study\u2019s results broaden the applicability of treatment for patients\u201d and possibly help lead to longer-term solutions for uveitis.", "answer": 1}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nHowever, the present results provide sufficient information to suggest that vaping does not increase infection rates and may in fact lead to a decrease in infections.\"\nSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels.\nThis misinformation includes a misreported study on rats that claimed that vaping may increase vulnerability to infections.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release is not the novelty of e-cigarettes but the novelty of the research. We give it a satisfactory for including this statement which puts the research in context:\n\u201cSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels. Human trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\u201d", "answer": 1}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nThe information about physical activity was reported by the participants, and it\u2019s likely that many were too generous in their estimates of how much time they spent at the gym.\nHowever, there are also some limitations to this study, the researchers say.\nThe researchers then cross-referenced this information with health department death records.\n\u201cI think that the weekend warrior physical activity pattern is beneficial because they are actually doing a large proportion of vigorous intensity activity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not establish what\u2019s novel, unlike what we saw in our review of The Guardian\u2019s story.", "answer": 0}, {"article": "The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nResults from the Phase 2 study, reported in the Journal of Neurosurgery on Dec. 18, 2015, demonstrated the safety of DBS in Alzheimer's patients.\nDr. Ponce adds that the next step is evaluating the efficacy and longer-term safety of the treatment, which will not be known until the last patient completes the two-year evaluation later this year.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release implies novelty by stating that the research \u201chelps pave the way\u201d for a new treatment option. Deep brain stimulation is used for other brain disorders, so it is obviously not a new device or new surgical approach, and the release makes this clear. However, as an approach to treat Alzheimer\u2019s disease it is novel.", "answer": 1}, {"article": "\"The goal is to create cells that are missing or defective in people.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\n\"It introduces a whole new paradigm for treating disease.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The approach described \u2013 while novel \u2013 is certainly not unique (viral vector for treatment of a chronic disease).\u00a0 Additional comments on the approach used by other reseachers would have added a needed balance.\n\u00a0", "answer": 0}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nOf 575 patients who randomly received the iodine-alcohol combination, 42 developed a surgical-site infection.\nRather than prepping patients with iodine-alcohol \u2014 a common antiseptic combination in C-sections \u2014 the research indicates that chlorhexidine-alcohol is significantly more effective.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nThe researchers argue that the evidence is strong enough to change standard skin-prep practices for C-sections.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release explained that other studies have examined skin-prep, but this one was the first to directly compare dual-element preps for C-sections. Here is an excerpt:\n\u201cPast trials comparing antiseptics before surgery included relatively few participants and often compared a chlorhexidine-alcohol combination with iodine alone. These studies could not determine whether the worse performance of iodine alone was due to the chlorhexidine, the alcohol or the combination.\u201d", "answer": 1}, {"article": "RA Nash et al.\nNew clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis (MS), an autoimmune disease in which the immune system attacks the central nervous system.\nOther studies have indicated that currently available MS drugs have lower success rates.\nFive years after HDIT/HCT, most trial participants remained in remission, and their MS had stabilized.\nFive years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This news release explains the significance of the study in supporting initiation of a randomized trial. However, the results are not entirely \u201cnew,\u201d as the release states; they were previously reported at a medical conference in June 2016. Also, we found it interesting that the published study states its results are consistent with three similar trials, including this Canadian study, bolstering the validity of its finding. Those trials are not mentioned in the news release.\nThe idea of using bone marrow transplantation for medical illnesses is not new. During the 1990s bone marrow transplantation following high dose chemotherapy was touted as a cure for breast cancer. \u00a0A randomized clinical trial was begun in the late \u201990s but was discontinued when results from the initial studies were found to\u00a0have been fraudulently reported. (Described in a book called \u201cFalse Hope: Bone Marrow\u00a0Transplantation for Breast Cancer\u201d by Peter D. Jacobson and Richard A.\u00a0Rettig.)", "answer": 0}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nIn addition, the mammoth, U.S.-government funded Women's Health Initiative (WHI) earlier found no negative link between calcium and heart health.\nDr. Susan V. Bukata, associate professor of orthopaedic surgery at the University of Rochester Medical Center, said that the study really doesn't provide enough information to make a definitive conclusion.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a great job explaining why these study findings are an important step in sorting out the role of calcium in heart health while showing that this study alone will not answer all the questions patients might have.\n", "answer": 1}, {"article": "(Editing by Jon Loades-Carter)\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nInvestor confidence in the antibody medicine, however, took a big hit in July 2008 when it failed to meet its main goal in a mid-stage trial and caused brain swelling at higher doses.\nRinne\u2019s imaging study was funded by Elan and Wyeth, which is now part of Pfizer.\n\u201cIt demonstrated that the drug has an effect on the pathological hallmark of Alzheimer\u2019s disease,\u201d lead researcher Juha Rinne from Finland\u2019s University of Turku told Reuters.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The drug reported on, bapineuzamab, is currently the focus of a number of clinical trials, many of which are recruiting participants. \u00a0(www.clinicaltrials.gov). \u00a0The focus of this story was on a very tiny study which was more about methodology for assessing Alzheimer\u2019s disease. \u00a0So while the story made it seem like it was reporting on a study of a novel drug, it failed to mention the much larger studies of this drug that are currently in the works.", "answer": 0}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nThe article provides new insights into the disease's manifestations in the retina and information on the optical imaging system.\nThis clinical trial is reinforced by an in-depth exploration of the accumulation of beta-amyloid in the retina of Alzheimer's patients versus matched controls, and a comparison analysis between retina and brain pathologies.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\nIn the new article, the researchers report on a 16-patient clinical trial to demonstrate the feasibility of identifying beta-amyloid in the eye using autofluorescence imaging.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes the novelty of the findings in several areas, noting:\nThe article provides new insights into the disease\u2019s manifestations in the retina and information on the optical imaging system. Here are several highlights:", "answer": 1}, {"article": "She wears her device while she sleeps.\nAnd the trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\nIn 2005, the FDA approved a device that stimulates another nerve that leads to the brain \u2014 the vagus nerve.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story a satisfactory score because it at least explained the following:\n\u201cthe trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.In 2005, the FDA approved a device that stimulates another nerve that leads to the brain \u2014 the vagus nerve. But stimulating the vagus nerve requires surgery to implant a device near the collarbone.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone.\u201d\n", "answer": 1}, {"article": "Because obesity is linked to poor outcomes for expectant mothers and babies -- including birth defects, gestational diabetes, high blood pressure, premature birth and even childhood obesity -- efforts to lose weight before pregnancy are important, said Dr. Aaron Caughey, chair of the department of obstetrics and gynecology at Oregon Health and Science University's School of Medicine.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\nThe investigators didn't examine what might have caused smaller babies among bariatric surgery recipients, or higher stillbirths.\nCaughey agreed with the researchers that any pregnancy occurring after weight-loss surgery merits a higher level of monitoring and should be considered high-risk.\n\"The positive effects of bariatric surgery on health outcomes -- such as diabetes and cardiovascular disease -- are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes,\" Johansson pointed out.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes the study author about previous research in this area. \u201cThe positive effects of bariatric surgery on health outcomes \u2014 such as diabetes and cardiovascular disease \u2014 are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes.\u201d We\u2019ll call that statement barely good enough for a satisfactory rating. The NEJM paper refers to a number of studies and reviews of studies examining this issue. It would have been nice to describe how the current study confirms or differs from those studies and why.", "answer": 1}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nThe technique developed is called DARC, which stands for detection of apoptosing retinal cells.\nNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma.\nWhile we cannot cure the disease, our test means treatment can start before symptoms begin.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers to the tool under development as a \u201cpioneering diagnostic.\u201d A researcher is quoted saying, \u201cNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma. While we cannot cure the disease, our test means treatment can start before symptoms begin. In the future, the test could also be used to diagnose other neurodegenerative diseases.\u201d\nWe\u2019ll give the release the benefit of the doubt that the test may potentially be novel for glaucoma but not for any neurological disease for which it hasn\u2019t even been tested.", "answer": 1}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nDr. Courtney Vito, a breast oncologic surgeon at the City of Hope Comprehensive Cancer Center in Duarte, Calif., was pleased that a serious issue in breast cancer treatment is getting a closer look.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nRazzini didn't know how much American patients might have to pay for such treatment, but added, \"Compared to other effective treatments such as antidepressants, (acupuncture) should be less expensive, and, for sure, more safe and feasible.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is the weakest spot for the story. We found\u00a0three other papers that evaluated acupuncture as a means of addressing hot flashes for cancer patients: this one from 2007, one from 2009, and another from 2009. The findings from the studies are not all in agreement (with each other, or with the study being discussed in this story).\nWhat does it tell us that we didn\u2019t already know? Does it build on previous work? Looking at all of the work on this subject, what do we know about this form of treatment? Those are good questions\u2013important questions\u2013and this story doesn\u2019t address them.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news hook here is the FDA approval of this drug combination. We\u2019ve already given the story credit for this above under \u201cAvailability.\u201d And we\u2019d note that just because the FDA approves something, doesn\u2019t mean that it\u2019s novel. There are plenty of \u201cme-too\u201d drugs out there, and this story doesn\u2019t make any attempt to clarify how this new drug combination works differently or better than existing drugs.", "answer": 0}, {"article": "For more on irregular heartbeats, visit the U.S. National Library of Medicine.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nIn essence, the new intervention -- known as \"visually guided laser-balloon catheter\" -- enables doctors to much more accurately target the so-called \"misfiring cells\" that emit the irregular electrical impulses that can cause an erratic heartbeat.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The word \"new\" was used five times in the short story.\u00a0 Yet the real novelty of this approach is only scantily and insufficiently described \u2013 especially if the implication is that this has relevance for 2.2 million Americans. ", "answer": 0}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\n\"These findings can be used to identify people who may benefit most from this type of intervention.\"\nThe researchers found 55 percent of patients with psoriasis and 62 percent of patients with psoriatic arthritis reported improvements in their disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "One could easily come away from this release thinking that these researchers are the first to report psoriasis symptom reduction in those undergoing bariatric surgery (with resultant weight loss). However, such findings have been reported before, and the release does not acknowledge this.", "answer": 0}, {"article": "\"Are [aromatase inhibitors] better than tamoxifen?\n\"In general, for postmenopausal women, we are offering them aromatase inhibitors based on the single studies that have been referenced [in these guidelines] and what has already been reported in national meetings.\"\nAromatase inhibitors are not effective in this age group, the experts note.\nThe paper, issued by the American Society of Clinical Oncologists (ASCO) and published July 12 in the Journal of Clinical Oncology essentially brings guidelines in alignment with today's practice.\nThe drugs can also cause side effects that need to be taken into account when prescribing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that tamoxifen is not new and that aromatase inhibitors \u201care a more recent entry into the field.\u201d The story also states that aromatase inhibitors have been a standard part of care before the guidelines\u00a0were released.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the procedure has been in use for decades. What could have used more exploration\u2013from independent sources\u2013is whether it\u2019s overused.", "answer": 1}, {"article": "It doesn't stay around long enough to cause hypoglycemia,\" he said.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nWhile Afrezza looks promising, it can't replace all injections for people with diabetes.\nCurrently, the only way to get that insulin is through injection or an insulin pump that must be inserted in a new site under the skin every few days.\nThis finding came after Exubera had been pulled from the market, and the sample size wasn't large enough to draw a definitive link between the drug and the increased risk of lung cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article doesn\u2019t explain how the inhaler technology differs from that used in Exubera, only that Afrezza is a dry powder dissolved in the lungs, absorbed into the bloodstream. \nAlso, from what we can see, the overall therapeutic role of Afrezza is no different than that of Exubera. People who need to take insulin to treat their diabetes would need injections of long-acting (basal) insulin and then puffs of mealtime (prandial) insulin. From what we are told in this story, the true novelty of Afrezza over Exubera would be a) its shorter mechanism of action and b) the fact that Exubera has ceased to be. They haven\u2019t demonstrated that Afrezza has a different safety profile in humans from that of Exubera. (Other sources we found quote Dr. Leone-Bay noting that the Afrezza inhaler has unique properties.) The claim of superior glucose control over injectable insulin is unsubstantiated in the story, yet it\u2019s critical information.", "answer": 0}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\nThese supplements are not regulated by the Food and Drug Administration, said Vazquez Roque.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "References to past research on seaweed supplements were made.", "answer": 1}, {"article": "The effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\nBergquist said he hoped the device could treat patients for whom the Levodopa drug, which turns into dopamine in the body and increases levels of the chemical, was not enough.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\n\u201cWhat we are hoping for with this device is to find a treatment for movement disorders where Levodopa, Parkinson\u2019s disease where Levodopa is not enough.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the TENS technology has found use in other areas of medicine.", "answer": 1}, {"article": "\"If someone really feels they need to take this and they need to try it, well go ahead and do it.\nStill, Schneider won't object if someone wants to try it.\nThe report, published in the Dec. 23-30 issue of the Journal of the American Medical Association, supports the findings of earlier, smaller studies.\nThis age group is not typical of the age of both healthy people and those with mild cognitive impairment who use ginkgo for improving mental performance.\"\nHowever, ginkgo was safe and no serious side effects were noted, DeKosky added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of these products is not in question. ", "answer": 2}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is story makes it clear this is a novel drug in the\u00a0early phase of testing. ", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\n\"HCA may be preferred as a therapy over CA (potassium citrate).\"\nThe most effective inhibitors reported in the literature simply stop the crystal from growing.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There do not appear to be any other studies available on www.PubMed.gov that look at hydroxycitrate as a potential kidney stone treatment.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\nThe new study gives \"very, very solid support\" for screening less often, Lichter said.\nThe last study is a warning to people who get screening tests that aren't recommended, or who question whether screening can ever hurt.\nHowever, if an HPV test was positive, a Pap test helped confirm or rule out the need for follow-up.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Where novelty was at issue, the story establishes novelty, saying, for example, \u201cThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\u201d", "answer": 1}, {"article": "Yet stroke patients admitted on the weekends were no more likely to die than stroke patients admitted during the week: 1,420 patients admitted on the weekend died versus 3,993 patients admitted on a weekday, which worked out to roughly the same rate of death.\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\nStroke requires emergency treatment and for those suffering a stroke on a Saturday or Sunday, \u201cwaiting until Monday for aggressive treatment is not an option,\u201d Dr. Abby S. Kazley and colleagues from the Medical University of South Carolina in Charleston emphasize in a report released today.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story does not suggest that tPA is a novel treatment for stroke.", "answer": 1}, {"article": "It needs to be tested in large trials,\" he said.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\nAnother trial in 2013, however, suggested that removing clots was not beneficial, he added.\nJolly said there are mechanical methods of removing clots, which were not tested in this study.\nHowever, preliminary results from small trials of mechanical clot removal have not been promising, Jolly noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that there was prior research on this topic showing benefit from clot removal.", "answer": 1}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nCollaborators on the study included first author Dr. Erin Howden, Research Fellow with UT Southwestern's Graduate School of Biomedical Sciences and the IEEM and now a faculty member at the Baker Heart and Diabetes Institute in Melbourne, Australia.\nThe new study appears in Circulation, a journal of the American Heart Association.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions early research by cardiologists from the same institution documenting stiff left ventricles in middle-aged people who don\u2019t exercise. It\u2019s mentioned that this study is unique in asking the question: can exercise restore heart elasticity in previously sedentary, middle-aged people?\nWe\u2019ll rate this satisfactory. But really, this is just one of innumerable studies that show exercise is beneficial. It might be measuring the benefit in a novel way but, in the end, it is just suggesting that exercise is good.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Physicians have treated Parkinson\u2019s patients with the drugs pergolide and cabergoline for a long time. The news article accurately represents their controversial history, though it neglects to note that other medicines in this drug class are avaliable that do not appear to cause heart valve disease.", "answer": 1}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the RapidArc may be new to the market, the story provided no insight as to how the radiation treatment from this device compares to others on the market. \u00a0Is it delivering something that is truly unique or are there other systems out there that can similarly focus the radiation beam used in treatment? (In fact \u2013 going to the company website, it appears that RapidArc is just a modification of existing intensity-modulated radiation therapy technology. The story says RapidArc is used in conjunction with IMRT and image-guided radiation therapy.\u00a0 But what does that mean?)", "answer": 0}, {"article": "CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\n\"Importantly, the fact that CAM2038 will be given in the clinic by health providers should address concerns about diversion of buprenorphine for illicit use.\nAbout CAM2038\n\nThe investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid use disorder are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.\n\"This study provides clinical proof of concept that CAM2038 will be an effective treatment for opioid use disorder,\" said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals, \"The current opioid crisis demands innovation, and CAM2038's novel technology is now one step closer to providing physicians and patients with a different approach to treating this deadly chronic disease.\"\nFour more trials, including two Phase 3 studies, are currently ongoing.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests the product under development is \u201cnovel\u201d and that it \u201chas the potential to alter the current treatment paradigm for opioid dependence.\u201d We aren\u2019t really told what is novel about the formula, though. A weekly or monthly administered opiate antagonist would be a new addition to the treatment options but it is not really novel.", "answer": 0}, {"article": "\"For research, there's a lot of value,\" Knopman says.\nThe goal in all this, according to the Alzheimer's Association, is to increase opportunities for earlier diagnosis and treatment.\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\nThat would be good for the Alzheimer's Association and the National Institute on Aging, which sponsored the work on the new criteria.\nThe new definitions, which were just published online by the journal Alzheimer's & Dementia, acknowledge this dimly understood early phase of Alzheimer's.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story summarizes key components of the new definitions of the stages of Alzheimer\u2019s disease that are different from those used in the 1984 guidelines. It points out that lab tests and brain scans have not been shown to be accurate and reliable in ways that would make them useful in clinical settings, as well as some of the questions that remain about how the results would be used.  A more complete description of which biomarkers are being studied would have been a good addition.", "answer": 1}, {"article": ".\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\nCanha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\nOverall, skin temperature and the bed temperature were higher in closed conditions than open conditions.\nIn the meantime, Mishra and colleagues monitored carbon dioxide levels, temperature, background noise and humidity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish what makes this research novel. It\u2019s fairly well-known that indoor air quality can be poor, and that ventilation can help circulate the air.", "answer": 0}, {"article": "Attention, memory, and language improved.\nThe Mediterranean diet can improve your mind, as well your heart, shows a study published in the open-access journal Frontiers in Nutrition.\nBy sticking to the Mediterranean diet the study showed that people had slowed rates of cognitive decline, reduced conversion to Alzheimer's, and improved cognitive function.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\nTwo of the included studies focused on younger adults and they both found improvements in cognition using computerized assessments.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Studies of this diet are numerous. Although this meta-analysis may be unique in its analytical characteristics, the text makes no claim for novelty.\nThe release includes quotes which make the study sound like new information, when it really isn\u2019t. For example:\n\u201cThe most surprising result was that the positive effects were found in countries around the whole world. So regardless of being located outside of what is considered the Mediterranean region, the positive cognitive effects of a higher adherence to a MedDiet were similar in all evaluated papers.\u201d", "answer": 0}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nJay lays out the hows and whys of spinal stimulation, and she paints a vivid picture of a life in agony, a journey that has included skeptical doctors, plenty of painkillers and unanswered questions about the future.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nBut she shares a similarity with those characters: Her all-too-human body has been upgraded with a machine.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Spinal cord stimulation appears to have been around for years, though the marketing of these devices appears to be on the upswing. One concern: The piece refers to her getting a \u201cnext generation stimulator. This implies that there is a prior generation one, and we\u2019re not sure what the difference is.", "answer": 1}, {"article": "\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\nWe hope to empower patients with new research about the long-term cardiovascular health benefits of a vegetarian diet, which include a reduced risk of a heart attack, stroke, and premature death.\"\nFor clinicians concerned about spending extra time in and outside of the exam room, the study authors encourage time-strapped health care providers to refer patients to registered dietitians who can help with the transition to a plant-based vegetarian diet.\nThe meta-analysis appears as an online advance in Nutrition Reviews.\nThey find:\n\nA plant-based vegetarian diet is associated with total cholesterol that's 29.2 mg/dL lower in observational studies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Is it novel to show that vegetarian diets are associated with lower cholesterol? Other studies have examined the relationship between vegetarian diets and plasma lipid levels, and comparing them with omnivorous diets, found there was no difference in high density lipoprotein cholesterol (HDL-c).\nWe wondered if there was some other aspect of the study that made it novel. The release notes that the study goal was to examine the association between a vegetarian diet and plasma lipid levels \u201cthroughout the lifespan.\u201d According to the published study, this was the first meta-analysis to do so on a \u201clong-term\u201d basis. However, to be included in the analysis, clinical trials and observational studies only had to be 4 weeks of duration \u2014 hardly \u201clong-term.\u201d\n\u00a0", "answer": 0}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\nBut getting the treatment to the right target in the body has presented a challenge.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nOther teams are using fats or lipids to deliver the therapy to the treatment target.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach is discussed appropriately. ", "answer": 1}, {"article": "She exercised.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\nEven more promising are the findings from the seven patients with early pancreatic cancer that were detectable through their protein levels.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\nFurther, levels dropped when patients had surgery to remove their tumors, so the marker could also be used to follow the progression of the disease, Kalluri said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The findings are presented as novel, but novelty is not established. There\u2019s no discussion of whether there has been other research into tests for pancreatic cancer and how the new test builds upon those previous efforts. We can infer that this is new, but the context is not established.", "answer": 0}, {"article": "The vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nThis finding is important for people who are trying to lose weight, including those suffering from metabolic syndrome and/or type 2 diabetes.\nHowever, subfascial fat was only reduced in response to the vegetarian diet, and intramuscular fat was more greatly reduced by the vegetarian diet.\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release describes what the study set out to do \u2014 measure changes in weight and in subfascial and intramuscular fat and how these change can impact metabolism. But the study isn\u2019t novel. Numerous studies have been conducted on the effects vegetarian diets have on different types of body fat as well as weight and metabolism.", "answer": 0}, {"article": "Thrombectomy involves a catheter placed in the femoral artery and snaked up the aorta and into the cerebral arteries where the clot that is blocking the artery, and causing the neurological symptoms, is retrieved.\nHowever, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\nThe trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\nTo select patients for the trial, the researchers used a new approach which used brain imaging and clinical criteria as opposed to just time alone.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release might have noted that previous research had suggested that some extension of the six-hour timetable for optimal clot removal was possible, even for medical therapy. But overall, the release makes clear why and how this trial was novel.", "answer": 1}, {"article": "Their median age was in the mid-50s, and they were followed for a median of 6.3 years.\nBut Dr. Carlson said that some of his colleagues, even after hearing the new study results, still thought the nodes should be removed.\nBut doctors have continued to think that even microscopic disease in the lymph nodes should be cut out to improve the odds of survival.\nNor is it known whether the findings could be applied to other types of cancer.\nThe new research grew out of efforts in the 1990s to minimize lymph node surgery in the armpit, called axillary dissection.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that a change in treatment protocol away from removing all the lymph nodes under the arms of women with breast cancer would be novel.\u00a0There is some nuance, here, though that could be missed by a casual reader. Women who have one to two positive lymph nodes would avoid having additional lymph node surgery. The overall tone of the story may make it appear to some readers that women get to avoid lymph node surgery altogether, but they don\u2019t.", "answer": 1}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cNow, we see it may reduce stroke risk in people older than 65.\"\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the study\u2019s focus was clear in the story.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes how the new tests wed radioactive tracing materials with an amino acid (in the case\u00a0of the prostate cancer) and other molecules, and sufficiently explains how the new tests differ from current nuclear images.", "answer": 1}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\nThe study was funded by grants from the Heffter Research Institute, the RiverStyx Foundation, William Linton, the Betsy Gordon Foundation, the McCormick family, the Fetzer Institute, George Goldsmith, Ekaterina Malievskaia and the National Institute on Drug Abuse (R01DA03889).\nThe researchers cautioned that the drug was given in tightly controlled conditions in the presence of two clinically trained monitors and said they do not recommend use of the compound outside of such a research or patient care setting.\nBoth studies are published in the Journal of Psychopharmacology on Dec. 1.\nAdditional authors included Matthew Johnson, Michael Carducci, Annie Umbricht, William Richards, Brian Richards, Mary Cosimano and Margaret Klinedinst, all of The Johns Hopkins University.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release places the work in the context of previous research from Johns Hopkins, which is enough \u2014 barely \u2014 to earn it a satisfactory rating here. What we would really like to see is how this work compares to previous research done specifically on the use of psilocybin to treat anxiety in cancer patients \u2014 such as this 2007 study, this one from 2011, or this one from 2013. We don\u2019t necessarily expect an exhaustive comparison, but there needs to be at least some recognition that other work has been done in this field over the past 10 years.", "answer": 1}, {"article": "There are some caveats to the study.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\nSo it\u2019s not really controversial to conclude that simultaneously using opioids and benzodiazepines dramatically increases the risk of drug overdose \u2014 or, conversely, that stopping the concurrent use of these two drugs could reduce the risk of overdose.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says researchers \u201cjust uncovered\u201d the danger of tandem opiod/benzodiazepine use and quotes a researcher saying the study \u201creveals an underappreciated policy lever for reducing drug overdoses: Making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\u201d\nIn fact, this has been the radar of the medical community for awhile. A 2015 study found veterans using opioids had a higher risk of death from drug overdose if they also used benzodiazepines. And last year two government agencies took action: The U.S. Centers for Disease Control and Prevention amended guidelines to discourage clinicians from prescribing both types of drugs simultaneously, while the FDA advised of the dangers of mixing the drugs and strengthened warning labels and patient medication guides for nearly 400 products.\nInstead, the challenge has been figuring out how to get patients off of this drug combination and recent\u00a0research/care delivery redesign efforts are tackling this issue (but this article doesn\u2019t not get into this at all, nor is this what the research study is about).", "answer": 0}, {"article": "Rather, surgeons move electronic instruments that are linked to the movement of other instruments inside the body, while they watch a three-dimensional image of what\u2019s going on inside.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nThe robot-surgeon team might not have outperformed the surgeon alone because the procedure was a relatively simple one.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nUsing a robot for basic surgery, like the kind studied here, would be like using a computer to do addition, he told Reuters Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here is that the humans beat the robots. It would have been nice to see at least a sentence about whether other studies had shown similar results with other types of surgeries. Was this the first man-vs.-machine study of this kind?", "answer": 0}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older.\nThis could lead to a better quality of life and more effective treatment based on which prostate cancer a man is diagnosed with.\nWhat they found was more than minimal differences among the tumors.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\nThese genes demonstrated the risk of the disease progression, which was more accurate than the currently used Gleason score test and PSA test.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The findings reported in the study seem to be newsworthy, and we\u2019ll give credit\u00a0for indicating that \u201cnew research has revealed\u201d and \u201cthis discovery\u201d as\u00a0establishing novelty. There\u2019s also a nod to previous research about prostate cancer genetics.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\n\u201cAlthough we found an association between women who experience less pain during labor and lower risk for postpartum depression, we do not know if effective pain control with epidural analgesia will assure avoidance of the condition,\u201d said Dr. Lim.\n\u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n\nThe researchers controlled for factors already known to increase the risk for postpartum depression, including pre-existing depression and anxiety, as well as post-delivery pain caused by tissue trauma during childbirth.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\nIn the study, researchers reviewed the medical records of 201 women who used epidural analgesia and had their pain assessed using a 0-10 scale during labor.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "While technically a novel result, it\u2019s a minor one. We found a 2014 study in Anesthesia & Analgesia that explored the same question, though in a Chinese population and with greater rigor. That study compared women who chose epidurals to those who chose a \u201cnatural\u201d birth without epidurals. Interestingly, we found a 2015 commentary that responds to this 2014 study \u2014 and it was authored by Lim (the lead author of the new study), who rightfully states that, if epidurals do decrease the risk for postpartum depression, then \u201cit could have tremendous ramifications on the long-term mental well-being of half of the world\u2019s population who are of child-bearing age.\u201d Lim\u2019s letter also called for more research with larger sample sizes to try and replicate the results. But roughly one year later, Lim\u2019s abstract explores the question with no overt controls and a similar sample size.", "answer": 0}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\n\"Patients participating in the study were nearly four times more likely to recommend ECP to their friends and family as compared to the standard colonoscopy prep.\"\n\"The ECP approach allows patients to eat solid food bars and drink palatable low-volume beverages, a patient-friendly design that participants in the study clearly favored over conventional preps,\" comments Dr. Siegel.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release uses the term \u201cnovel\u201d to describe this new prep formulation. \u00a0Although a variety of preps are now available, this study\u2019s novelty appears to be its high level of patient satisfaction.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story establish the true novelty of the approach?", "explanation": "What appears to be \u201cnew\u201d is the explosion of combing salons and newer prescription shampoos, as well as the review article published last week that evaluates them.", "answer": 1}, {"article": "Both the American Heart Association and the World Health Organization recommend getting at least 150 minutes of moderate- to high-intensity physical activity a week for cardiovascular and overall health.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\n\u201cOur study takes this a bit further and shows that exercise may also have a role in preventing people developing depression in the first place.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Exercise for mental health is not a new concept. What makes this study novel is that it\u2019s looking at exercise\u2019s potential to prevent depression, and if that impact would be useful enough for a public health level initiative. As the study explains:\n\u201cWhile many agencies are keen to promote the potential mental health benefits of exercise, at present the literature is unable to provide the most basic information needed for effective, targeted, evidence-based public health campaigns concerning depression and anxiety.\u201d\nThe story didn\u2019t explain this.", "answer": 0}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nThe NeuroStar system resembles a dentist's chair.\nIt can cost as much as $400 for a 37-minute session and require multiple treatments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the device approved in 2008 is novel as is the underlying approach to treating depression", "answer": 1}, {"article": "\"The Suboxone got me far enough away to look and say 'wow, look at your life.\nUnlike methadone, Suboxone can be prescribed by any doctor, even a family physician, so treatment for addicts can now be convenient and discreet.\nPatients in the trial are given counseling as well as a new kind of anti-addiction drug called Suboxone.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\nIf left unsatisfied, the receptor sends pain signals to the brain - this is withdrawal.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment in places implies the drug is new and novel (by referring to the current clinical trial, by using the word \"new\" to describe it, and by emphasizing its hope for revolutionalizing treatment). But it also states that it is currently available. This leaves the viewer uncertain about what\u2019s \"new\" here.\nSo what is new? Buprenorphine has been an approved parenteral analgesic for decades. The drug was approved in 2002 as an alternative to methadone\u2013a drug to be taken as a more benign replacement for the more addicting drug being abused, such as heroin. It enables withdrawal from the addicitive drug, which may be followed by other addiction treatments or maintenance therapy.\u00a0 \nThe current trial involves only patients who are addicted to painkiller medications like OxyContin. The study is designed to determine whether those taking Suboxone and getting supportive counseling can taper off Suboxone fairly quickly and become entirely drug-free.\u00a0\u00a0 ", "answer": 0}, {"article": "Learning skills for positive emotions result in less HIV in blood and less anti-depressant use\n\u2022 Positive emotions are possible even with stress of chronic health problems\n\u2022 Men using positive emotion skills learned to cope with their stress, while control group went on anti-depressants\n\nCHICAGO --- When individuals recently diagnosed with HIV were coached to practice skills to help them experience positive emotions, the result was less HIV in their blood and lower antidepressant use, reports a new Northwestern Medicine study.\nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV.\nBased on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\nThe HIV study is part of a larger body of positive affect research being conducted by Moskowitz.\nThe positive emotion intervention also improved mental health.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release contains this claim of novelty:\n\u201cThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV. Based on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\u201d\nWe believe others in medicine have probably used \u201cpositive\u201d intervention before, but they may have called it support or emotional coaching or many other phrases. Cognitive-behavioral therapy, massage, and other means to improve a person\u2019s coping skills could be considered \u201cpositive emotion intervention.\u201d", "answer": 0}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nResults of a late-stage study of the drug in melanoma patients will be detailed in a \u201clate-breaker\u201d session at ASCO\u2019s annual meeting in June.\nThe abstract was one of thousands of studies released on Thursday ahead of presentation at the American Society of Clinical Oncology (ASCO) next month in Chicago.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story points out that what is new about the highlighted trial is that it looks at using this experimental drug in a subset of patients, those with melanoma that has spread to the brain. However, readers might be misled by the apparently inaccurate description of the second trial in the story, as noted above.", "answer": 1}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nNow, researchers say a special scoring system might point to those people at highest risk for colon cancer, who may need the test the most.\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\nImperiale's team noted that not all people deemed to be at \"average risk\" for colon cancer face the same risk of the disease, and so some might benefit more from invasive colonoscopy than others.\n\"A risk stratification tool is critical in helping physicians make appropriate screening recommendations for patients,\" Garbus said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it sound as if this is a first-of-its-kind tool. However, risk calculation tools for colon cancer have been in circulation for many years.", "answer": 0}, {"article": "Oxytocin is produced naturally in the bodies of humans and animals.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nAlthough more research is needed to confirm and explore the findings, the results are the latest in a growing body of evidence indicating that the hormone could lead to ways to help people with the often devastating brain disorder function better.\nBut Sirigu was among those who said the finding should encourage more research on the potential benefits of oxytocin itself, especially for children.\nWhile cautioning that more research is needed on children and additional patients to make sure oxytocin is safe and effective, advocates for families with children with autism welcomed the findings.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that there have been previous studies of oxytocin in autism.", "answer": 1}, {"article": "\u201cThe lamp we\u2019re using at the moment costs less than $1,000, and you can imagine that if it were put into general circulation, the price would drop dramatically,\u201d he says.\nPrevious research has also shown that far-UVC light can kill MRSA bacteria, a common cause of infections after surgery.\nEarlier studies, on animals and humans, have shown that exposure to far-UVC light does indeed appear to be safe.\nNow, Brenner and his colleagues have show that UVC light can effectively kill airborne influenza.\nThe researchers suspected that it can penetrate and destroy microscopic bacteria and viruses, but can\u2019t travel through the protective outer layers of human skin or eyes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is made clear the authors have studied this type of light in killing methicillin-resistant staph. aureus (MRSA), but it\u2019s not clear if the current study is the first to apply far-UVC light to an influenza virus (in the published study the authors claim this is the first time far-UVC light has been assessed for inactivating aerosolized viruses).", "answer": 0}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nThe disease most often strikes adults after age 20, but it can develop in children.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story indicates that other studies have found a link between vitamin D and MS.\u00a0 ", "answer": 1}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story could have\u00a0provided more background on the history of\u00a0anti-addiction vaccines (a\u00a0heroin vaccine was explored in the 1970s), the treatments being explored now are different from\u00a0anything currently available. So we don\u2019t think this story overstates the\u00a0novelty\u00a0of the research.", "answer": 1}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provided an engaging look at the potential benefit for\u00a0deep brain stimulation to improve the condition of people in a minimally conscious state.", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe research team is now looking to fund a full clinical trial.\nThe test involves inserting urine samples into the Odoreader that are then measured using algorithms developed by the research team at the University of Liverpool and UWE Bristol.\nThe research team used a gas chromatography sensor system called Odoreader that was developed by a team led by Professor Probert and Professor Norman Ratcliffe at UWE Bristol.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The device is similar to many other technologies in development that are said to \u201csniff\u201d cancer based on specific odor signatures. But the release makes it sound as though this device is unique.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Pap smears rely on using a microscope to hunt for cancer cells, whereas the newer methods described use genetic testing. The story also notes how ultrasound and genetic blood tests for uterine cancers typically are used only when symptoms arise \u2014 an advanced stage of the cancers \u2014 since the those tests \u201cfail to detect many cancers, and also send up a lot of false alarms.\u201d The article places extra emphasis on so-called \u201cliquid biopsies,\u201d saying thy \u201chold the promise of revolutionizing cancer screening\u201d due to a lack of early screenings for these cancers. (That remains to be seen.)", "answer": 1}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nA once-a-day drug being developed to treat women with low libido proved to boost desire and led to better sex among female patients participating in late-stage studies, according to publications presented today during a medical meeting in Lyon, France.\nWomen who took the medicine, known as flibanserin, reported 22 percent more \"satisfying sexual events\" than those given a placebo in two clinical tests of 1,378 patients, according to abstracts released today at the European Society for Sexual Medicine annual meeting in Lyon, France.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story is accurate in stating that\u00a0if approved, flibanserin would be the first drug of its kind for pre-menopausal women.\u00a0 It does acknowledge that\u00a0other efforts to produce a similar drug have been unsuccessful. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that the new recommendations represent a departure from existing guidelines.", "answer": 1}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\n\"With further study, it may also be possible to analyze exhaled breath and urine samples to identify other cancer types, as well.\"\n\"We've now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages,\" says Prof. Zeiri.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not make clear that urine and breath tests have existed and been used for breast cancer, but the novel part of this study is the statistical analysis and modeling.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story establish the true novelty of the approach?", "explanation": "In the story Yale cardiologist Harlan Krumholz \u201csaid it represents one of the first times a professional medical society has looked at the appropriateness of its care in such a comprehensive fashion. \u201cIt needs to be a wake-up call for the rest of medicine to say this is what we need,\u201d he said.", "answer": 1}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nIt is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.\nThe study was funded by Pfizer Inc and the National Institutes of Health (5P30 CA16520-25).\nThese tools can help to individualize patient therapy going forward.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The drug is the first of a new class of drugs and that\u2019s noted in the release. ", "answer": 1}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n\u201cWho the heck knows what the active ingredients are?\u201d\n\nMarion Nestle, a nutrition expert at New York University, said the effects might not be unique to pomegranate juice.\n\u201cThis study does not demonstrate anything special about pomegranate juice,\u201d she told Reuters Health in an e-mail.\nAccording to the findings, among 50 patients drinking pomegranate juice for a year, about two would have to go to the hospital at least twice.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good job on this, citing research over at the last 3 years, but also concluding with this quote from Marion Nestle:\n\u201cThis study does not demonstrate anything special about pomegranate juice.The effects of juice were compared to a placebo, not to any other kind of juice that might have exactly the same effect. \u2026The pomegranate people are spending millions to prove what I could have told them in the first place. Pomegranate juices \u2014 like most if not all fruit and vegetable juices \u2014 have antioxidant activity. Does this make pomegranates better than any other fruit? Investigators have yet to show this.\u201d", "answer": 1}, {"article": "Hot flashes typically begin in the year or so before menopause and tend to abate in the years afterward.\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\nThe 2,000-year-old treatment is widely used around the world, according to the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health (NIH).\nThat's because hot flashes have a high placebo-response rate: Symptoms often improve, at least temporarily, with a dummy treatment.\nExperts in women's health say they are one of the most common ailments for which women use alternative medicine and that interest in non-hormonal treatments has increased as a result of the WHI findings.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Article notes that acupuncture has been used for more than 2,000 years.", "answer": 1}, {"article": "The fibers within the tendons fray.\nBut that cautionary experiment and others didn\u2019t slow the ascent of cortisone (also known as corticosteroids).\n\u201cThey change the pain biology in the short term.\u201d But, he said, cortisone shots do \u201cnot heal the structural damage\u201d underlying the pain.\n\u201cIt\u2019s not insignificant, but it\u2019s not kidney stones.\u201d\n\nSo the question of whether cortisone shots still make sense as a treatment for tendinopathies, especially tennis elbow, depends, Dr. Khan said, on how you choose \u201cto balance short-term pain relief versus the likelihood\u201d of longer-term negative outcomes.\nThe shots were quite effective, providing rapid relief of pain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe article specified that steroid injections have been employed for roughly half a century.\n", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story establish the true novelty of the approach?", "explanation": "A bit of historical information in the story makes it clear that online therapeutic agents have been around\u2014in various stages of development\u2014for more than a decade.", "answer": 1}, {"article": "\"People say, 'What's the harm in screening?'\nOthers were highly critical, noting that prostate cancer death rates have plummeted in many countries after they instituted widespread PSA screening.\nSeveral other experts said that the new recommendations strike a careful balance, and that they hope they might discourage large-scale screenings where the risks and benefits are not carefully laid out.\nMen younger than 75 should be carefully counseled about the potential risks associated with the test and the lack of evidence about any benefit before getting it, the panel said.\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was reporting on the release of new guidelines from the US Preventive Services task force, and highlighted that these recommendations differ from the previous version in that they specify that the benefit of routine screening of men older than 75 years of age for prostate cancer is little to none while at the same time, the harms are moderate-to-substantial.", "answer": 1}, {"article": "Most American women begin to experience menopause around age 50, with some changes in their menstrual cycles earlier.\n\u201cThis requires a thorough exam and a thorough history, and individualized care, but women need to know: It\u2019s not a death sentence or a dependence.\nToo many women have been taught to accept suffering in this stage of life, they say.\nThe sheer number of choices today and the need for a thorough initial health assessment make the decision on hormone therapy highly dependent on close communication between a woman and her doctor, experts say.\nSuch custom compounds are not FDA-approved.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is nothing novel about the approaches described in the story.", "answer": 2}, {"article": "\"Usually we expect the results of a phase 1 clinical trial to give us data that we can use to guide the results of future treatments.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nWorking with Borges's Young Women's Breast Cancer Translational Program at CU Cancer Center, young investigator Elena Shagisultanova, MD, PhD, recently earned a $1.4m competitive ASPIRE grant from Pfizer, Inc., to conduct a clinical trial exploring the use of tucatinib against so-called \"triple positive\" breast cancer - those cancers driven by both estrogen and progesterone receptors and the HER2/neu oncogene.\n'There are women who are alive today because of this drug,' says University of Colorado Cancer center researcher\n\nPhase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests that tucatinib is unusual because it is taken in pill form, meaning women do not need to visit infusion centers for treatment. It also suggests that tucatinib is unusual because of its small molecular size, enabling the drug to pass the blood-brain barrier. However, no information is provided about how many, or how few, other cancer drugs can be taken in pill form or whether any other anti-cancer drugs currently in use or in testing also can pass through the blood-brain barrier.", "answer": 1}, {"article": "And women who had ovaries removed reduced their risk of ovarian cancer by as much as 80 percent.\nWhile surgical decisions are up to patients, the findings of this study should help them decide what to do, she says.\nAnd, today, she says she feels physically strong again.\nOne of the women who decided to take that chance is 61-year-old Toby of New Jersey.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story points out that this latest study is building on earlier work.", "answer": 1}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\n\"These findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release is fairly clear that the meta-analysis has uncovered/confirmed that statistical misinformation can result from even the best intentioned efforts to improve diagnostic criteria and staging. It would have helped for the release to connect the dots and demonstrate what those data are and what their impact would have on various patients.", "answer": 1}, {"article": "\"I'm not sure I'd want to sign up for that one before I had longer-term results,\" Califf said.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nAnd though statins are widely used and most often successful, an alternative to them would be welcome, Ladenson said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t put this study into the context\u00a0 of other research on alternatives to statins. ", "answer": 0}, {"article": "Angioplasty remains the top treatment for people having a heart attack or hospitalized with worsening symptoms.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nThe new study shifts the argument from which type of stent to use to whether to do the procedure at all.\nAn even bigger surprise: Angioplasty gave only slight and temporary relief from chest pain, the main reason it is done.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that stenting is not a new idea.", "answer": 1}, {"article": "Asians are at high risk of developing diabetes even at a healthy weight.\nThis is the first study to report how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\nThe study also touches on the financial implications of these guidelines.\nBut O'Brien said it is unclear whether insurers will be required to pay for diabetes screening if patients only meet the expanded criteria.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the study is the first to \u201creport on how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\u201d It also mentions that the research builds the study author\u2019s previous work. As noted above, the release should have included more hard data from the study to back up its argument. ", "answer": 1}, {"article": "\u201cIt\u2019s something you don\u2019t have to figure out,\u201d he said.\nIn the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\n\nCraven estimated the coconut-water market at about $100 million annually right now, but companies are doubling their sales year after year.\n\u201cIf you focus on coconut oil, you lose out on the fiber and you are focusing on a concentrated source of calories.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\nIt\u2019s the whole coconut that needs to be talked about.\u201d\n\nEntrepreneurs are talking about the whole coconut these days.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make it clear how novel coconut products are or whether they offer any benefits not offered by a regular, balanced diet or why.\u00a0There is certainly nothing new about coconuts. The story does not explain whether there is any new information that provides a rationale for increased attention to coconuts or whether the attention is fueled entirely by marketing.", "answer": 0}, {"article": "This article has been updated to include more information on DMAU.\nMore attractive to many men than a long-acting injection or topical gel\u2014both of which are in development\u2014the prototype pill offers a \u201cmajor step forward\u201d in male contraception, Stephanie Page, a professor at the University of Washington in Seattle and senior investigator on the study, said in a statement.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nResearchers have developed a prototype male pill that appears to be safe in a month-long trial.\n\u201cDespite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,\u201d Page said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A 1980 journal article trumpeted \u201cChina Invents Male Birth Control Pill.\u201d 2003 saw the publication of a book titled \u201cThe Male Pill: A Biography of a Technology in the Making.\u201d As recently as 2016, news releases have talked about research such as \u201cmale birth control shots\u201d that \u201cprevent pregnancy\u201d (we reviewed that one). In short, research into pharmaceutical contraceptives for men has been an active field for decades \u2014 and premature announcements of breakthroughs date back at least 38 years. This story quotes a researcher involved in the recent study as saying the findings are a \u201cmajor step forward\u201d and are \u201cunprecedented in the development of a prototype male pill.\u201d But it doesn\u2019t tell us why. What makes this study, or this pill, different?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the popularity of knee replacement is expanding from older people to younger ones, suggesting that the operation is not new.", "answer": 1}, {"article": "His doctor prescribed a C.P.A.P.\nIt is also more expensive, and it doesn\u2019t work for every patient.\nIn those people, Provent typically doesn\u2019t work.\n\u201cIt works like a champ in some people and doesn\u2019t work on other people,\u201d said Dr. Nancy Appelblatt, an ear, nose and throat surgeon in Sacramento who has prescribed it to about 100 patients.\nDr. Lee A. Surkin, a cardiologist and sleep medicine specialist in Greenville, N.C., said patients typically start with a 10-day trial pack that costs $27.50.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story begins by contrasting this new treatment with the existing treatment. It says \u201cFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing. C.P.A.P. reduces and in some cases completely prevents episodes of apnea. But the mask is like something from a bad science fiction movie: big, bulky and obtrusive. Many patients simply refuse to wear it or rip it off while asleep. Studies show that about half of all people prescribed C.P.A.P. machines stop using them in one to three weeks.\u201d The story makes the claim that the Provent patch is \u201cfar less intrusive than the traditional C.P.A.P. machine.\u201d The claim of novelty is not backed up by the evidence presented in the story or by any published clinical trial.\u00a0 As we noted above about one out of every six people using the Provent in the study stopped using it after 3 months.", "answer": 0}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that laminectomy is one of the most common operations performed in the U.S., suggesting that it is not novel. Most readers likely know that nonoperative treatments such as pain medications and physical therapy are not new.", "answer": 1}, {"article": "Smith also embarked on a new diet, cutting out dairy and red meat.\nBut others caution that Fertilome is just the latest genetic test promising more than it can deliver \u2014 and, in this case, playing to the fears of women who are anxious about becoming a mother.\nAnd even the company\u2019s founder and CEO acknowledges the test can\u2019t provide clear and definitive answers on which treatments women should try next if they\u2019re struggling with infertility.\nBut the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor.\nSo a patient may see a table showing that her genetic variants make her twice as likely to have a condition known as recurrent pregnancy loss, defined as repeated miscarriages.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Many fertility clinics offer genetic testing. It is possible that Fertilome is unique to the extent that it looks for nearly 50 genetic variants. But the story doesn\u2019t clearly explain how this is different from other genetic tests that may be offered to help couples conceive.", "answer": 0}, {"article": "Currently, the most popular drugs to treat depression are called selective serotonin reuptake inhibitors, or SSRIs.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nMoskal, however, said he is confident that this drug will be a breakthrough in treating depression.\nBecause the drug targets these areas of the brain it might also help people with other problems such as schizophrenia, bipolar disorder, anxiety and Alzheimer's disease, the researchers suggested.\nFRIDAY, Dec. 7, 2012 (HealthDay News) -- An experimental antidepressant that targets the brain in a different way appears to both act fast and last long, researchers say.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is also a mixed bag. The story got rid of some of the more scientific jargon that was included in the press release, but in the process, some bits became ambiguous. Establishing novelty is one example. This is a novel approach; no drugs on the market have the same mechanism.\u00a0 There is intense interest in this field by the National Institutes of Health. The story states, \u201cMoskal\u2019s team developed a new way to target the brain\u2019s NMDA (N-methyl-D-aspartate) receptor\u2026\u201d but in fact, other antagonists, such as the anesthetic ketamine, work in a somewhat similar fashion.\u00a0 GLYX-13 targets brain receptors responsible for learning and memory, which is a different approach from most popular antidepressants that work by improving levels of the hormone serotonin. Although pieces of this information are stated in the article, this does not clearly come across to the reader. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "D.C.I.S.\nTo Dr. Norton, the most important conclusion to be drawn from the study is that more research on breast cancer prevention is needed.\nBased on those findings, it is easy to see why raloxifene was declared the winner.\nBut it's not clear that women concerned strictly about breast cancer will line up for this drug, either.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that raloxifene is an existing drug but that Eli Lilly is asking the FDA to approve it for another purpose.", "answer": 1}, {"article": "The Department of Nutrition, Exercise and Sports conducts research, education, innovation, and dissemination of information in nutrition, human physiology and sports at the highest international level, and incorporates the humanities as well as health and social sciences.\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN).\nWhile we are looking into other biomarkers, it is quite amazing how much more we can do for our patients just by using those two simple biomarkers.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The idea that vegetables, fruits, whole grains, and healthy fats should be recommended for weight loss is hardly new. And yet the release frames these results as \u201cpotentially [leading] to a breakthrough in personalized nutrition.\u201d We\u2019d need more proof of tangible benefits before agreeing with that characterization.\u00a0", "answer": 0}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nStill, some researchers not involved in the study said the topic required more work.\nIf such studies were funded by the government, which sustains a lot of academic research, taxpayers would bear the burden for what the company would eventually profit from, he said.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that gradually cutting down on smoking, with the help of patches and gum, is an established way to change habits. However, it suggests that the current study \u201cis the first that appears to show the same for pills,\u201d which is not entirely accurate. As noted above, the competing drug\u00a0bupropion has been studied in this context and shown to offer potential benefits. Since this is essentially the same problem that we noted above under \u201cAlternatives,\u201d however, we won\u2019t penalize the story again for this omission.", "answer": 1}, {"article": "One recent study, for example, found that pregnant women who started taking selective serotonin reuptake inhibitors (SSRIs) in the second or third trimester had a higher risk of preterm delivery than other women.\nIt is unclear, Manber said, why acupuncture might help lessen the severity of depression.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\nAll completed a standard measure of depression severity at the outset and again after four and eight weeks of treatment.\nOverall, 63 percent responded to the therapy, versus 37 percent of the \u201ccontrol\u201d acupuncture group and half of the massage group, according to findings published in the medical journal Obstetrics & Gynecology.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story described the use of acupuncture for treating patients with chronic pain, but it did not mention previous studies that evaluated its use in depression. ", "answer": 0}, {"article": "Lower disk herniation results when the insulating disks that sit between spinal vertebrae tear open, allowing jelly-like material to protrude and exert pressure on surrounding nerve roots.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Best case, I think [pRF] could be an option for people if they [have already] failed therapy and medication,\" said Park.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains early on that pRT is \u201cnot new\u201d although it\u2019s claimed that recent technology advances enable doctors to deploy it with better accuracy.", "answer": 1}, {"article": "Currently, an early Alzheimer's diagnosis requires complex brain scans.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The broadcast did lay out for viewers that currently, it is only after death that Alzehimer\u2019s disease can be definitely diagnosed and so if this test were demonstrated to be valid, it would represent something new.", "answer": 1}, {"article": "\"Chantix increased the unpleasant effects of alcohol, for example feeling drowsy and irritable, [and] participants also reported that they didn't like the alcohol effects as much,\" Childs said.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\nWEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned above, other drugs are already used to treat alcohol addiction. Readers of this story should have been given that background.", "answer": 0}, {"article": "The most common side effects include itchiness and irritation in the mouth, ears and eyes, swelling of the mouth or tongue, headache and gastrointestinal problems like stomach pain and heartburn.\nKnown as sublingual immunotherapy, the treatment relies on the same principles as traditional allergy shots, but is delivered by tablets or drops that dissolve under the tongue.\nDr. Harold Nelson, an allergist at National Jewish Health in Denver, said that the body of evidence indicates that sublingual immunotherapy beats antihistamines and other medications used to control hay fever symptoms.\nA study published earlier this year \u2014 and not included in the current analysis \u2014 found that during that post-treatment year, Grazax patients had one-quarter fewer hay fever symptoms than those who had been given a placebo for comparison.\nResearch so far suggests that the symptom relief persists in the year after patients stop taking Grazax.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nBy mentionsing that trials from 1995 were included in the meta-analysis, the story lets readers know that sublingual allergens are not novel. The concept of administering allergens orally has been proposed as early as 1900. \n", "answer": 1}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\nIn the second trial, a significant improvement was seen in 66.1 percent of the drug-treated patients, compared with 26.9 percent in the control group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes no unfounded claims about novelty, and the story makes it clear that an effective topical treatment via wipes would be new for this condition.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This ties in to what we said above regarding alternatives. By explaining several surgical interventions that address uterine fibroids, the story clearly articulates what is novel about the Sonata approach. Well done.", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nThe research also determined that the best surgical approach for cochlear implant procedures did not involve drilling into the bone around the ear.\nThis research was supported by the National Institute on Deafness and Other Communication Disorders the National Center for Advanced Translational Sciences.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\n\"This study is a breakthrough for patients with hearing loss, and improvements in practice and techniques will allow them to enjoy many hearing benefits such as music enjoyment, listening in complex environments, and sound localization.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t tell us anything about the novelty of the wireless cochlear implants nor that of the \u201cround window\u201d (where surgeons open the membrane without bone removal or drilling in the inner ear) and \u201ccochleostomy\u201d (which requires drilling into the bone to get inside the inner ear). \u00a0Are these new procedures? \u00a0What other research has been done on them? \u00a0Where is the context that establishes the place of these in the current landscape of hearing-preservation technologies?", "answer": 0}, {"article": "Ellis also is a McNair Scholar at Baylor.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nFurthermore, these tumor cells were sensitive to an experimental drug, neratinib.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release made it seem that neratinib was an experimental drug that could be used for women with a particular gene mutation related to HER2+ metastatic breast cancer. It wasn\u2019t made clear that neratinib is already used to treat early-stage HER2+ breast cancer.", "answer": 0}, {"article": "EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.\nPost-dose reduction flares resolved when the original dose of TNFi was restarted.\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t establish novelty. The implication is that the approach is new, but is this the very first time that such a strategy has been tested? If so, where did the idea come from? If not, what did previous studies of this approach find? A bit of background would have been useful.", "answer": 0}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nThe patients had been recruited and treated with the virus in England by a team led by Dr. Amit C. Nathwani of University College London; researchers at the Children\u2019s Hospital of Philadelphia monitored their immune reactions.\nDr. Nathwani and his team reported that they treated the patients by infusing the delivery virus into their veins.\nTwenty more patients will be treated to assess the best dose of the virus, the goal being the highest dose that does not set off an immune system attack, Dr. Tuddenham said.\nThe patient cannot be injected again with the same virus because his immune system is now primed to attack it.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach \u2013 both for what it apparently achieved \u2013 and for how it builds on past research \u2013 was clear in the story.", "answer": 1}, {"article": "In addition, Drs.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\nBeing able to identify this lung cancer \u201csignature\u201d through a simple breath test has emerged as one of the most promising ways to diagnose the disease.\nNewswise \u2014 Chicago \u2014 A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make a strong claim of novelty \u2014 and that\u2019s appropriate.\nA quick online search found that besides this research from the University of Louisville in Kentucky, at least two other institutions are developing breath tests for lung cancer detection: Georgia Institute of Technology and the Winship Cancer Institute of Emory University\u00a0 and the University of Leicester.\nThe release said \u201cA subset of four VOCs\u2014called carbonyl compounds because of their carbon base\u2014have been discovered in the exhaled breath of lung cancer patients.\u201d Discoveries sound novel. But this study, more than a decade old, describes the use of VOCs for lung cancer detection. \nWhile the release doesn\u2019t claim to be \u201cfirst,\u201d it might have mentioned related work that has been done in this field of research.", "answer": 0}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nBut, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nStandard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\nAnother sleep specialist said the findings show \"some potential benefit\" from suvorexant, but he cautioned insomnia sufferers against relying completely on any drug.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "One of the independent experts addressed the drug\u2019s relative novelty in this section:\n\u201csuvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake. Standard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\n\u201cThe way [suvorexant] works makes a lot of sense,\u201d Bazil said. \u201cThe hope is that it will help some people who haven\u2019t responded to [other drugs], and have fewer side effects.\u201d", "answer": 1}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nThe laboratory experiments were set up to mimic the conditions within the human digestive system, specifically the stomach, small intestine and three regions of the colon, to study how polyphenols are broken down and absorbed.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions the study is \u201ca first-of-its-kind trial\u201d of humans combined with a parallel laboratory study.\nIt\u2019s mentioned in the published study that, to the authors\u2019 knowledge, this is the \u201cfirst microbiota/metabolome investigation of the impact and fate of tart cherries and their polyphenols in the human colon.\u201d", "answer": 1}, {"article": "\"The endometrium feeds the baby up until the eighth week of pregnancy.\nFor women who suffer multiple pregnancy losses in the first four to six weeks of gestation, the hormone progesterone could offer hope for a successful birth, according to a new study by Yale School of Medicine researchers and their colleagues at University of Illinois at Chicago.\nThe researchers believe that the progesterone caused the patients' endometrium to produce more endometrial secretions.\nWomen in the study with an abnormal nCyclinE level were prescribed progesterone two days after ovulation, when the uterine lining matures in preparation for a possible pregnancy.\nAn abnormal EFT is associated with pregnancy failure, while a normal EFT is associated with pregnancy success.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This release doesn\u2019t establish the novelty of this approach. Other research studies have looked at the use of progesterone in preventing miscarriages.\nAccording to the reference site \u201cUpToDate\u201d by medical publishers Wolter Kluwer, more than 50 research studies have examined the use of progesterone in preventing miscarriage or pre-term birth, with mixed results.", "answer": 0}, {"article": "Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The braces studied were appropriately not portrayed as a new treatment approach.", "answer": 1}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nThe vaccine is recommended for optional use in boys and men.\nBoth of these vaccines are recommended to prevent cervical cancers.\nThe Gardasil vaccine has also received FDA approval for prevention of genital warts.\nThese vaccines are now on the CDC\u2019s routine childhood vaccine schedule for girls starting at age 9.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good history and context given about the two vaccines \u2013 Gardasil and Cervarix. Better than competing HealthDay on this count.", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that the drug is on the market and used for related conditions, but its use in relapsing-remitting MS patients is being explored in this research.", "answer": 1}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0This story failed to mention that peer reviewed studies examining the utility of PCA3 have not found it to be significantly associated with progression of prostate cancer.\u00a0 Reporting on the results of this recent study, based on information from a company spokesperson without examining what others may have found to date is inadequate.\n", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The focus of the story is IVM as a newer method of fertility treatment.\u00a0 The story is clear that there have not been many births from this method. ", "answer": 1}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly notes that these techniques were originally developed for use in brain surgeries, but are now being considered for use in a variety of other procedures \u2014 and have been since at least 2011.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that researchers are exploring a new use of an existing product.\u00a0 ", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that CAD is a newer method of reading mammographies, but in a recent observational trial it was no better\u2013and may have produced more false positives\u2013than images read and interpreted by radiologists alone.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nNumerous vaccines to prevent breast cancer recurrence are currently under study, he noted.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\nThe study involved 217 breast cancer survivors who had gone through their treatment and were free of disease at the start of the trial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story stated that \u201cNumerous vaccines to prevent breast cancer recurrence are currently under study\u201d but didn\u2019t explain how the vaccine in question is different than any of those other approaches.", "answer": 0}, {"article": "It has been truly motivating to work with a technology that will help transform the way that we monitor and treat individuals with cancer.\nAccording to the report in The Journal of Molecular Diagnostics, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer.\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.\nAfter generation of customized mutation detection assays, the researchers were able to identify tumor-derived circulating DNA from three out of six patients.\nIn contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes novelty here:\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nWhile he called his study's findings encouraging, Dr. Merriam declined to characterize them as a breakthrough, saying more work is needed to determine both the safety and the benefits of the treatment.\nThe study did not examine whether the medication improved cognitive functioning.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Promoting growth hormone to counteract the effects of aging, namely physical functioning, is not new. However, the benefit of this has not been established and safety of growth hormone for this use in older adults in unknown. The story does note that this study does not represent a breakthrough in preventing age-related decline in physical or cognitive functioning. ", "answer": 1}, {"article": "These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the \"Actavis plc\" name).\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nThe new advancement is an addition to Allergan's current eye care portfolio.\nStudy 2 is a prospective, single-arm, multicenter, open-label clinical trial in which participants used TrueTear\u2122 to stimulate tear production for 180 days.\nINDICATION \n\nTrueTear\u2122 provides a temporary increase in tear production during neurostimulation in adult patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says this is the first neurostimulator intended to increase tear production in patients with dry eye problems.", "answer": 1}, {"article": "But they can have large effects on muscles and joints, often making muscles work as much as 50 percent harder for the same movement and increasing stress on joints by a similar amount.\nThe findings were somewhat puzzling: While the group that used inserts had about half as many injuries \u2014 defined as pain that kept them from exercising for at least half a day \u2014 there was no obvious relation between the insert a soldier chose and his biomechanics without it.\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\nThey added, though, that the research was inadequate for them to have confidence in those conclusions.\nThe only indication seems to be that a comfortable orthotic might be better than none at all, at least for the activities of people in the military.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The shoe inserts described in this study are widely available and are not particularly novel in concept or design. The article did not \u201chype\u201d particular orthotics because of innovative characteristics or qualities.\n\u00a0\n", "answer": 1}, {"article": "The study described in the article \"Effect of Foeniculum vulgare Mill.\n\"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\nThe study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news hook here is that results of this\u00a0study are billed as \u201cconfirmation\u201d of benefits \u2014 an overstatement \u2014 but also that the study is one of the first undertaken with scientific rigor. It\u2019s hard to say if that is so, but the release makes a reasonable case, albeit based on a very brief trial.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the true novelty of the approach?", "explanation": "Described within this story as \u2018a new device\u2019 and that \u2018about 100 hospitals around the country already are using the treatment\u2019 which suggest that this is a relatively new approach.", "answer": 1}, {"article": "The average age of the participants was 11.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\nBut, researchers believe it may interact with a brain receptor that plays a role in the development of seizures, Devinsky said.\n\"We don't know the real effect of the cannabidiol, and we won't until we complete the studies that are ongoing that are placebo-controlled and blinded,\" added Brooks-Kayal, who is also a professor of pediatrics, neurology and pharmaceutical sciences at the University of Colorado School of Medicine.\nPrevious studies have shown some benefit in adults, and word has spread.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since cannabis has been used for the treatment of seizures for centuries, it\u2019s curious why the researchers didn\u2019t test the compound in a better designed trial (randomized, blinded and placebo controlled). The public and patients are still left with the question of whether this works. But the story does briefly mention previous studies that have looked at cannibidiol in adults, so the story gets a pass here.", "answer": 1}, {"article": "He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\nThe study -- billed as the world's largest randomized, controlled trial of acupuncture in the emergency department -- included 528 patients.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It would be pretty novel if the study had shown that acupuncture was more effective than conventional analgesic drugs in controlling pain, but that\u2019s not what this study showed. While\u00a0both the study and the story\u00a0did seem to indicate that acupuncture was as effective as either painkillers or painkillers and acupuncture, the\u00a0abstract of the study\u00a0also said \u201cnone of the examined therapies provided optimal acute analgesia.\u201d Controlling pain was arguably the reason the study\u2019s patients went to the emergency departments. The study basically said acupuncture was as good as painkillers for pain control but that for these patients, neither was successful. We think that should have been explained in the story to help establish the novelty of this research.", "answer": 0}, {"article": "\"Done haphazardly and irregularly, it is probably worse than no breast self-exam at all,\" Steiner said.\nIt defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good.\nWhat is clear is that studies don't supply an answer that fits all women.\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\nShe encourages women to schedule an appointment devoted to learning the technique, which should take at least a half-hour.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Breast self-exam is not novel; neither are the recommendations being discussed. The story explains how public health education campaigns influenced the widespread promotion of BSE for every woman, and that such recommendations are no longer appropriate based on available evidence. ", "answer": 1}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nShe said babies in her study might have received more DHA than those in this study.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\nDr. Oken said the new study might have shown no benefit in 18-month-olds because effects in infants might be \u201chard to measure\u201d or \u201cit may be that the benefit of DHA is not as important as when you\u2019re 4.\u201d\n\nDr. Makrides\u2019s team plans assessments at 4 and 7.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The past research on this topic was made clear. ", "answer": 1}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The research discussed here is novel in a general sense, but the story doesn\u2019t establish this to a satisfactory degree. A number of previous studies have looked at saliva markers of Alzheimer\u2019s, and there are probably dozens of other blood tests, scans, and other approaches currently in development to address the diagnosis of Alzheimer\u2019s disease. The story does not allude to this research", "answer": 0}, {"article": "For decades, the message about fats has been relatively simple \u2014 reduce the amount of oils and fats you eat from animal and dairy products (less red meat and cheese) and substitute them with healthier fats from plants or fish (olive oil, omega-3 fatty acids).\nThe study is actually a reanalysis of data that had not been included in the original publication of results from the Sydney Diet Heart Study, a trial that was conducted from 1966 to 1973.\nReviewing the dietary advice as a whole is important, says Alice Lichtenstein, a spokesperson for the association, since changes in one area could have unexpected, and potentially harmful, effects on other eating habits.\nThe latest results, however, raise questions about that advice.\nRamsden says the findings provide some refined understanding of unsaturated fats, which come in different chemical forms that may have varying benefits or risks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the mortality findings of this study were previously reported in 1978, and that the cardiovascular findings are new. That\u2019s more detail than HealthDay provided.", "answer": 1}, {"article": "\u201cYou don\u2019t need any fancy equipment.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n\u201cThe basis of autism in the brain is very deep.\nThere may be very little that one can actually change about the disorder for an individual with a severe case,\u201d Lange said.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the test is unclear from this story. Diffusion tensor imaging is not new and it has been used in previously published reports, a fact not provided to the reader. The way in which it was used was new and novel. We usually take people to task for suggesting a drug or medical device or procedure is novel when it is perhaps not. The story should have indicated that although the scanners used were conventional and others have employed the technique described, the programming is novel and not routinely available.", "answer": 0}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\nThe same is true for 88 percent of CRT-D patients, they noted.\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of these devices or of remote monitoring is never established. The story also could have established the relative novelty of the dataset.\u00a0 The manufacturers\u2019 patient registry allowed the researchers to study the real world events in people living with ICD\u2019s and CRT-D\u2019s. The story does not note the rather unique circumstances allowing the research to be conducted; a manufacturer\u2019s patient registry.", "answer": 0}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that using a follow-on booster of the high-dose vaccine is a novel flu prevention strategy in patients with cancers that affect the immune system. This approach of adding a booster is used in immune-suppressed patients with\u00a0other vaccines as well.", "answer": 1}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\nUse of this approach is likely to have major benefits for both patients and healthcare providers.\nThese patients are therefore potentially suitable for immediate and safe discharge from the emergency department.\nThe overwhelming majority of these patients do not have a heart attack.\nThis study was funded by the British Heart Foundation and Chief Scientists Office (Scotland).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news hook for this release is pretty well established.", "answer": 1}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\n\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study.\nThirteen of the women taking the drug for an additional five years developed breast cancer in the opposite breast during the study, compared with 31 taking the placebo; 55 and 68, respectively, developed a recurrence of cancer in the original breast.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately establishes the novelty of the study:\n\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study.\n\u201c\u2026If you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\nThis is important because many patients already continue aromatase inhibitors:\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years. There had been no research on whether that was beneficial.", "answer": 1}, {"article": "\"It is a definite nuisance.\nThe study, published in the April issue of the International Journal of Radiation Oncology, Biology, Physics, also found that acupuncture relieved the heart palpitations and anxiety often associated with hormone therapy for prostate cancer.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nIn the study, researchers followed 14 men who were taking hormone therapy for prostate cancer and suffered from hot flashes.\nThe findings don't confirm that the ancient Chinese discipline relieves hot flashes, and only 14 men participated in the study, which was conducted by researchers at New York Methodist Hospital and Weill Cornell Medical College of Cornell University.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No context was given for placing this research into the bigger picture of what else is doing for the hot flash problem, or if other related acupuncture research has been done.\nA study (Harding C, et al) was published in the British Journal of Urology International in January 2009, reporting on a larger pilot study of 60 men with advanced prostate cancer who did show substantial symptomatic improvement. Those authors called for randomized trials to more definitively determine benefit.", "answer": 0}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\nThe company, 6SensorLabs, has started taking pre-orders for the device it calls Nima, which can test food for gluten and get rapid results, said co-founder and chief technology officer Scott Sundvor.\nThe company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is not the only product under the sun designed to quick-test for gluten, although to be fair, it\u2019s unclear whether another product would be better/worse/as good. A quick online search identified\u00a0a number of consumer kits available. It is unclear why a story focusing specifically on this particular device is news.", "answer": 0}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says, \u201cSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\u201d Quoting the author, though, does not prove that the approach is novel.\u00a0The study itself also says that the findings are novel: \u201cSignificantly, this is the first report of an interdependent biological role for distinct HECT E3 ubiquitin ligase isoforms, and highlights an entirely novel regulatory paradigm that selectively limits the level of inhibitory and activating Smads.\u201d Of course, that would not make much sense to most readers. So the story should have found a way to explain to readers why the approach to cancer treatment identified was a true advance that opened a new world of possibilities or whether it was a small improvement. And having an independent source evaluate the novelty would have helped as well.", "answer": 0}, {"article": "Sacroiliac joint dysfunction is a common cause of disabling pain in the lower back, buttocks, or groin.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\nThe minimally invasive SIJ implant approach evaluated in this trial has been cleared by the US Food and Drug Administration.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release identifies the study as the first randomized trial of a surgical procedure versus conservative,non-surgical care for SIJ dysfunction.", "answer": 1}, {"article": "Surgery also typically involves significant breast tissue damage and disfigurement due to large incisions and removal of sizable breast mass.\nThe ICE3 trial, which began patient enrollment in October 2014, will significantly expand data on the technique as a treatment for breast cancer.\nUtilizing IceCure Medical's innovative IceSense3\u2122 cryoablation system, the multi-center trial is examining cryoablation of certain types of breast cancer.\nFollowing numerous limited studies, a growing number of women are now being treated with the technique as part of a groundbreaking clinical trial involving leading breast cancer specialists across the country.\nWe are confident that the ICE3 trial can prove certain women can be successfully treated less aggressively than in the past.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Breast cancer isn\u2019t normally treated with cryoablation, and the release makes this clear. We\u2019re also told the improvements built into ICE3 makes treating cancer with it \u201cmore precise\u201d and reliable.", "answer": 1}, {"article": "It\u2019s very apparent that he\u2019s dying.\u2019\u201d\n\nLandon began to refuse chemotherapy and turn into a \u201clittle psychopath,\u201d says Riddle.\nIt also allowed sick children to access the drug under professional guidance.\nBut there\u2019s also an emerging body of research that suggests marijuana might be effective as a treatment for cancer on its own, or in conjunction with standard therapies.\n\u201cCombined with other targeted therapies, which again, specifically target the leukemia, you give it a one-two punch and hopefully reduce side effects and improve efficacy of treatment,\u201d he says.\nThe theory seemed to be especially promising for leukemia, at least according to studies done on cancer cells in test tubes and on mice injected with human leukemia cells.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that people have been using marijuana, including cannabis oil, to treat symptoms and side effects of cancer treatment for some time now. It notes that hypotheses about a direct effect on cancer are relatively new\u2026 and remain to be tested in people.", "answer": 1}, {"article": "1.\nThe study is published in Annals of Internal Medicine.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "What\u2019s novel about this study is the longer term relief gained from the therapies. The study points this out, but the release doesn\u2019t explicitly mention it.", "answer": 0}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nBut even if later school start times only improve sleep time, that\u2019s a positive step for public health.\nWhen it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nThere are some limitations to mention about the new meta-analysis.\nIn all, the researchers call for more rigorous data on the topic.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The reader will learn that the effects of eight or nine hours of sleep a night on teenagers have been demonstrated in other studies. What is novel is the meta-analysis\u2019 reflections on the big picture, which suggests caution in\u00a0making school policy changes on the basis of extant studies.", "answer": 1}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\n\u201cThey wanted to know where they could get (the hormone) after the study was over.\u201d\n\nBut that\u2019s jumping the gun, she warned, because the treatment is still experimental and GHRH is not approved to treat mental decline.\nIt\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\nStill, both Baker and Petersen said more work is needed to gauge the long-term consequences of GHRH injections.\nAn expert who wasn\u2019t involved in the research echoed the cautions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We think there could have at least been a line in the story about whether this is groundbreaking research looking at GHRH and mental function or whether there\u2019s been some track record.", "answer": 0}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\nThose who took the highest doses saw their recurrence risk drop by half.\n\u201cIf this is the case, dosage shouldn\u2019t matter.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is this odd quote in the story from the study author. \u201cObviously this is just one study, and it is observational,\u201d he says. \u201cBut if these findings are confirmed, this is pretty profound.\u201d This could have been a great opportunity for the reporter to explain what he means by an observational study and how much, much, much more work on a much larger group of patients would be necessary before statins could be safely recommended as a cancer treatment. Instead, the quote just ends on a positive note.", "answer": 0}, {"article": "\"We're embedding complexity and novelty into their daily lives, something that tends to disappear once people retire.\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\nOne strength of this study, she says, is that the participants were followed for two years, which in this case was long enough to see changes that wouldn't have been detected after just one year.\nShe says the program increases involvement in so many different kinds of activities that retired people may not have engaged in otherwise.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study concept \u2014 a randomized controlled trial of a civic engagement program \u2014 is novel and builds upon findings from a smaller pilot study. However, the release doesn\u2019t establish what is new or different about the study compared with previous research.", "answer": 0}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the test is similar to the company\u2019s genetic test to identify more lethal breast cancers, yet that it is the first such test for colon cancer. ", "answer": 1}, {"article": "Keytruda thereby met its main goal of the study.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nPatients whose tumors had especially high levels of PD-L1 also went longer without a progression of disease than those taking docetaxel, Merck said.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does explain, in broad terms, the novel way in which Keytruda and a competing cancer immunotherapy drug, work. The story also talks about the expected economic impact of cancer immunotherapies broadly. So we\u2019ll give the benefit of the doubt on the rating. However, it\u2019s not clear how many cancer immunotherapy drugs are on the market \u2014 just these two? A dozen? More? The story also doesn\u2019t tell readers how many of these drugs are approved for use against lung cancer. Is it just Keytruda?", "answer": 1}, {"article": "Ellison says she tried meditation, but her mind kept wandering.\nOn the other hand, Rabiner says, neurofeedback may offer something other treatments can't.\nAnd one chapter of the book is devoted to neurofeedback.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\nIn the meantime, he says, the study has shown that it is possible to do neurofeedback research that involves a placebo.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not oversell the novelty of neurofeedback for the treatment of ADHD.", "answer": 1}, {"article": "Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it's clear that \"some women with metastatic breast cancer have benefited from Avastin, but others not only have not benefited, they've been harmed.\nThursday, Woodcock held out the possibility that Avastin might eventually prove helpful in a targeted group of patients.\nThe announcement does not affect Avastin's status as an approved therapy for lung cancer, kidney cancer, colorectal cancer and brain cancer.\nThe results of those studies were a bitter pill for patients thriving on Avastin and researchers excited by the promise of the early data.\nThursday's announcement is only a first step in removing the FDA's approval for this drug in treating breast cancer patients.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "N/A", "answer": 2}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Recommended pneumonia vaccinations in older adults and those with compromised immune and respiratory systems is not new.\u00a0 The story focused on new recommendations that all adult smokers be vaccinated. ", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that this is the first trial to show a reduction in major cardiovascular events among patients taking this type of fish oil derivative.", "answer": 1}, {"article": "Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\nFor this study, the researchers recruited 39 middle-aged, overweight or obese volunteers with prediabetes and sleep apnea.\n\"Assessment of sleep apnea should be considered in patients at high risk for diabetes and cardiovascular disease, since our study shows that treatment of sleep apnea can reduce these risks.\"\nThe National Institutes of Health, plus the Diabetes Research and Training Center and the Institute for Translational Medicine at the University of Chicago funded this study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is one of the main limitations of the release. An online search shows that a number of studies have been done on the impact of CPAP use on patients with prediabetes and on patients with type 2 diabetes. The news release does not make clear how this most recent paper expands on the previous work \u2014 and it is important for releases like this one to place the new study in context.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nBronchial thermoplasty is indeed a relatively new approach to treating asthma. However, almost all of the trial results reported in this story were announced more than a year ago. The news is that the researchers recently presented results from the second year of follow-up at a medical meeting. However, the new information was barely mentioned in the story.", "answer": 1}, {"article": "\"Cancer patients tend to develop clots in their legs and lungs more frequently and also patients who develop clots in their legs and lungs tend to develop cancer more frequently,\" Choe noted.\nAn initial review at six years suggested that those taking the combination therapy had a 43 percent reduced risk of dying from prostate cancer, while side effects were not \"major,\" Mason said.\nOf the blood thinners used in the study, aspirin was the one which seemed to account for most of the benefit, the researchers said\n\nThere has already been some evidence that cancer and the body's coagulation system might be linked in some way.\nMONDAY, Oct. 25, 2010 (HealthDay News) -- One of the world's most ubiquitous and pedestrian drugs -- aspirin -- may cut the risk of dying for men who have prostate cancer that has not yet spread beyond the gland, a new study suggests.\nThe study included 5,275 men diagnosed with prostate cancer that had not yet spread beyond the prostate gland and had been treated with surgery or radiation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story notes that lab tests and other clues about cancer and blood coagulation have suggested that anticoagulants might have some effects, but that there has been little work that looks at these questions in people who have tumors that have not spread beyond the prostate.", "answer": 1}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article explains that this type of study had been conducted before with the WHI.\nBut we would have hoped for a little more explanatory background and context.\u00a0 The article doesn\u2019t adequately address the point that it is a novel study, because it looks specifically at early menopausal women and effects of hormone therapy on blood vessels \u2013 a not unreasonable early surrogate for harder endpoints such as CV disease events. The findings are actually not novel. The WHI analysis of a subset of younger menopausal women, published in 2007, showed that there was less coronary artery calcification in women treated with Estrogen and Progesterone compared with those who took placebo; a finding the KRONOS researcher thought they would also see, but did not. (They report a nonsignificant trend toward less calcification).", "answer": 0}, {"article": ".\nThe control group, however, had no clinically relevant alterations in their microbiota composition, Luzi said.\nLuzi said scientists now know that an impaired gut microbiota can alter the brain's signals for appetite and satiety, or fullness.\nHe and his co-workers studied whether dTMS could improve the gut microbiota composition in obese persons and, if so, by what underlying mechanisms.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release confirms that dTMS has been around for a while and is used to treat other conditions, but highlights that using the procedure to treat obesity is a new area of exploration.", "answer": 1}, {"article": "Parkinson\u2019s disease is a progressive neurological disease that causes symptoms including muscle tremors, shaking, and stiffness.\nThis was an observational study and therefore can\u2019t establish cause and effect.\nNor is it clear why the results differed for men and women.\nThe study doesn\u2019t prove that berries (or flavonoids in any other food) prevent Parkinson\u2019s disease.\n\"Our findings suggest that flavonoids, specifically a group called anthocyanins, may have neuroprotective effects.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story allows the researcher to claim that \u201cthis is the first study in humans to examine\u201d this association.\u00a0 We don\u2019t know whether that\u2019s true or not.\u00a0 And the story didn\u2019t provide any independent perspective to reflect on whether this is novel or not. But there\u2019s been a lot of other flavonoid research which the story could have at least mentioned.\u00a0 From this story, one might assume that this is the first study that\u2019s ever recognized flavonoids.", "answer": 0}, {"article": "This slowly progressive enlargement of the prostate can make urination difficult or painful and send men trudging to the bathroom many times during the day and night.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nNor does it lead to cancer.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\ncan lead to serious health problems for some.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did an acceptable job laying out the currently available approaches to BPH management; it also mentioned research with Botox for use in treating BPH as well as the novel use\u00a0of erectile dysfunction drugs for treating BPH.", "answer": 1}, {"article": "METs, or metabolic equivalents, are a measure of physiological measure expressing the energy cost of physical activities.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nThere were other significant findings too - notably that starting or restarting physical activity during retirement reduced the risk of death by two-thirds, but in contrast any reduction, even in low levels of activity, exposed the elderly to a higher risk of death.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\nIn commenting on the results, Dr Hupin said several conclusions might be drawn but notably that the level of physical activity in the elderly was negatively associated with mortality rate in a \"dose-dependent\" way and that even a low level of exercise below current recommendations had some protective effect.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There have been numerous studies on the benefits of exercise for the general population. Physicians currently recommend exercising for 30 minutes a day for at least five days a week, which \u201chas been shown to reduce the average risk of death by 30%,\u201d according to an uncited source in the news release.\nWhat\u2019s new, says the news release, is that \u201ca correlation between the level of physical activity and risk of death has not been so clearly determined in the elderly.\u201d\nBut we found these studies online, some going as far back as 1989, that state the association between regular physical activity and decreased mortality in older adults. In addition, recommendations are already in place for older adults, who are urged to exercise moderately and daily by the CDC.\nWe\u2019re not sure why the physical activity recommendations for the elderly warrant revision, as stated by the release, or what exactly is new with this research.", "answer": 0}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\nIt includes the options any oncologist addresses: surgery, chemotherapy and radiation and their side effects.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "By all accounts, this is the first randomized controlled study to show that providing palliative care\u00a0early after a\u00a0diagnosis of advanced cancer improves survival and other outcomes. The story accurately characterizes the significance of this. ", "answer": 1}, {"article": "\"I'm single, I'm bouncing around, and I'd like the opportunity to have a family, so I just figured, 'Why not?'\nAll told, costs can easily exceed $40,000, money Montoro doesn't have.\nAnd yet, even Widra agrees that egg freezing has appeal if it can help avoid the anguish of infertility.\nBut the limit is tricky to impose.\nThe bigger challenge, Sher and others say, is reaching out to younger women \u2014 getting them to take action before it's too late.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a decent job of explaining that the technique is experimental.", "answer": 1}, {"article": "Since IVM results in lower fertilization rates, protocols that use IVM are more likely to also use intracytoplasmic sperm injection (ICSI), in which one sperm is injected into one egg.\n\u201cUltimately, you want to do the best for the patient so my preference would not be IVM.\u201d\nWho is IVM helpful for?\nWhat are the limitations of IVM?\nYet most studies have found that IVF is superior to IVM.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned earlier, it\u2019s hard to say just why Fox is presenting this as \u201cnews now.\u201d", "answer": 0}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\n\u201cWhen Madrigrano told me about it, I thought it was an ingenious idea and I\u2019m glad it was developed,\u201d said Nancy Morrissey, who underwent lumpectomy surgery at Rush in July using the SAVI SCOUT technology.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\nUsing the SAVI SCOUT system technology, which emits 50 million radar pulses per second, surgeons can target the affected tissue within 1 millimeter of the reflector.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims that the Savi Scout is novel and that Rush is the first institution in Illinois to deploy the technology.", "answer": 1}, {"article": "Newswise \u2014 Columbus, OH.\nNow, with support from Ohio State\u2019s Center for Clinical and Translational Science (CCTS), researchers from both the College of Engineering and the College of Medicine are taking the technology to the next level.\nMade of silk and silver, the experimental dressing includes a self-contained battery that delivers a continuous, safe, low-level electrical current to the injury.\nThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As the news release points out,\u00a0FDA-approved\u00a0WEDs already exist on the market. What is the real novelty here? We are told:\n\u201cThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\u201d\nBut the release never explains what these\u00a0significant advances are.", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nNoonan says the research team has used these data to guide two other ongoing MILs clinical trials.\nNoonan says the small trial helped her and her colleagues learn more about which patients may benefit from MILs therapy.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nOne year after receiving the MILs therapy, 13 of the 22 patients had at least a partial response to the therapy, meaning that their cancers had shrunk by at least 50 percent.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We like the fact that the headline itself defines this as a \u201cpilot\u201d clinical trial and that the lede says that it is \u201cwhat is believed to be the first small clinical trial of its kind.\u201d\u00a0 Those kinds of qualifiers both declare the specifics of the research and also provide informative caveats, allowing the reader to gauge how much credence to give to the findings.\u00a0 All too many other medical releases fail to provide this measured approach.", "answer": 1}, {"article": "Menopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\nSanten and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\nA comprehensive review published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism focuses on current and future approaches to management of menopausal symptoms after breast cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Besides listing lifestyle approaches which are not novel, it\u2019s unclear if the emerging approaches listed are novel.", "answer": 0}, {"article": "Even the issues of how much vitamin D adults should take and whether calcium supplements help keep bones strong have been matters of debate.\nStill, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\nA preliminary report in July packed a surprise: No direct evidence was found that testing patients for low bone density helped avoid broken bones.\nAlso missing, Nelson said, are randomized studies that would indicate how often patients should be screened.\nFor Dr. Douglas C. Bauer, a professor at the University of California-San Francisco and a researcher who also treats many osteoporosis patients, the hardest decision is when to stop the drugs in patients who still have low bone density after five years of treatment but are not especially frail.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article discussed management approaches to osteoporosis that are well established\u2014though in some cases uNPRoven. Discussion of their novelty wasn\u2019t necessary. ", "answer": 2}, {"article": "\"Here, fertility is very important to many young women,\" he said.\nAnd for 15 of the women, transplantation had taken place more than five years earlier, the researchers said.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\nAnd no cancer developed in the transplanted tissue, Jensen said.\nTUESDAY, Oct. 6, 2015 (HealthDay News) -- Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Apparently, it isn\u2019t new to remove an ovary and freeze it. Some of the patients in the study had that done 15 years ago. The story establishes this and explains that the study is new in that it reports on longer-term outcomes.", "answer": 1}, {"article": "These plaques, which are caused by blood cholesterol, build up over time and cause arteries to narrow, leading to heart disease as the heart works harder to pump blood through the body.\nUp to now, however, there's been little evidence showing that a calcium scan can provide a solid assessment of a person's long-term health risk, the study authors said in background information.\nPeople with many calcium deposits can improve their long-term prospects by eating right, exercising, and taking medication to treat heart risk factors such as high blood pressure, elevated blood cholesterol and type 2 diabetes, Shaw said.\n\"The best use is in patients who have no symptoms, but the value of the test is not well known.\"\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story specifically notes that CAC testing is not new, and that previous research hasn\u2019t assessed long-term health risks associated with CAC.", "answer": 1}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nDr. Claudia Henschke, a clinical professor of radiology at Mount Sinai Medical Center and a longtime advocate for use of CT to screen for lung cancer, said the study was likely to have underestimated the benefits of CT scans because participants were screened only three times.\nBut Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York, said no one should rush out and get a CT scan yet because further analysis will better define whom the screening helped.\nThe study, called the National Lung Screening Trial, was conducted by the American College of Radiology Imaging Network and the cancer institute.\nHad the screening continued for 10 years, as many as 80 percent of lung cancer deaths could have been averted, she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story recaps some of the history of research on screening for lung cancer and quotes one of the researchers saying, \u201cThis is the first time that we have seen clear evidence of a significant reduction in lung cancer mortality with a screening test in a randomized controlled trial.\u201d", "answer": 1}, {"article": "Shares of Zafgen, which traded as high as $55.36 on the Nasdaq stock exchange last year, closed Tuesday at $5.62, down nearly 3.3 percent for the day.\nZafgen has not identified the patients who died or said at which of 14 US trial sites they were taking the drug.\n\u201cThis is the first demonstration of a clinical benefit against two of the major issues that affect this patient population.\n\u201cAs of today, we have no evidence to suggest that Beloranib by itself can cause blood clots,\u201d Hughes said.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Having stated that there are currently no treatments for Prader-Willi, the novelty of the beloranib should be\u00a0self-evident to the reader.", "answer": 1}, {"article": "Nighttime and morning BP decreased more profoundly on average -8/3.5 mm Hg for SBP/DBP, respectively.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nMelatonin ws effective in synchronizing disrupted circadian rhythms of BP, heart rate and body temperature, making these circadian rhythms smoother and less irregular.\nIncreased blood pressure and reduced robustness of circadian rhythms are frequently reported in elderly subjects.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t make a claim to novelty, but then it shouldn\u2019t as this study doesn\u2019t appear to offer anything new. Melatonin\u2019s main job in the body is to regulate night and day cycles or sleep-wake cycles. Many researchers have explored the\u00a0effects of melatonin supplements, and one 2010 review noted that its use was well established \u201cespecially\u201d for sleep disorders, including those related to aging.\u00a0 Much research has also determined that melatonin reduces night-time blood pressure levels in those with hypertension.", "answer": 0}, {"article": "\u201cRemember this day.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nLead researcher Martin Reck of Germany\u2019s Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard \u201cfrom today\u201d.\nThe second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\nResults of Bristol\u2019s failed Opdivo trial, which included patients with tumors testing only 5 percent or higher for PD-L1 against the 50 percent cut-off used by Merck, were also presented at ESMO.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that these findings reveal that immunotherapy works better when patients are prescreened for a specific genetic marker known as PD-L1, versus giving it to anyone with this type of cancer. It also\u00a0explains that the smaller second trial, mixing Keytruda with chemotherapy, was \u201cthe first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\u201d", "answer": 1}, {"article": "In another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Neither story was very clear on this point, but the WebMD story did not make a claim of novelty the way the AP story did. Contrast the two leads:\nWebMD: \u201cA new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\u201d\nAP: \u201cNew research offers hope for the first pill to treat a common problem in young women: fibroids in the uterus. The growths can cause pain, heavy bleeding and fertility problems, and they are the leading cause of hysterectomies.\u201d\nWe\u2019ll give a lukewarm \u201csatisfactory\u201d grade.", "answer": 1}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\nIf the method holds up, doctors could start patients on drugs such as statins far earlier than they do now \u2014 in time to save them from ever developing serious heart disease, the researchers report in the journal Science Translational Medicine.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story focuses on the use of inflammatory heart tissue as having potentially better predictive value than current risk assessment tools for heart attack. But it\u2019s a reluctant satisfactory, because the narrative is confusing and no\u00a0numbers were given to estimate the scope of the potential benefit\u2013how well the new approach worked.", "answer": 1}, {"article": "A variety of detox diets claim to flush toxins out of the body, aid weight loss and even clear up skin.\nI'm not missing the coffee,\" said viewer Rose Marie Volpe, who tried out the plan.\nBecause of that promised quick fix, the detox diet business is booming.\n\"I just really feel it gives your body a chance to re-set itself,\" she added.\nVolpe said she noticed results when her pants began getting baggy around her legs.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There was actually no discussion about the history of the products highlighted in this broadcast other than to indicate that they are all the rage. \u00a0Are they new? \u00a0One could not discern this from the segment.", "answer": 0}, {"article": "Esler's team found that more than 83 percent of those who had denervation treatment before had a drop in systolic blood pressure of at least 10 mmHg after six months and almost 79 percent maintained the reduction at 12 months.\nThe procedure is safe as well as effective, the study authors said.\nMONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\nWhether this technique might be useful in treating less severe high blood pressure hasn't yet been tested.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t reference any of the other of a growing list of other approaches to resistant hypertension.\u00a0 See some of our recent blog posts on this issue:", "answer": 0}, {"article": "The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nThis was an initial clinical trial designed to test for safety.\nBut, even if that's not possible, the recovery of some beta cell function would be welcome news.\nZhao's team developed a completely new approach.\nBoth groups were given stem cell educator therapy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear that this treatment is a new approach.", "answer": 1}, {"article": "Only children with moderate cough and severe stuffy nose were eligible, and those were divided into three groups.\nAlthough Vicks VapoRub is often used to fight colds and congestion, there has never been proof of how well it works.\nThere were no side effects in the two other groups.\nThe current study shows that Vaporub is more effective than placebo.\"\nThe next day parents were questioned about their child's symptoms overnight.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nAlthough, there\u2019s nothing new about VapoRub, the story does point out that the product claims have not been tested in this way before.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was correct in presenting the \"paint\" as a new possible adjunct to the methods used for determining tumor boundaries.", "answer": 1}, {"article": "\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nThis new approach places them right on the scalp.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\nSince then, the technique has been refined.\nA small electrical current seems to work by affecting pain centers deep within the brain, somehow muffling the perception of pain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment makes clear that while this particular application of electrical stimulation is novel, it has been in development and used for other purposes for many years. ", "answer": 1}, {"article": "He says he plays basketball with his granddaughter, works on his farm, and gets on the treadmill for 30 minutes three times a week.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nThe breakthrough comes just as researchers were becoming discouraged by studies in which bone-marrow stem cells failed to heal damaged hearts.\nHare was not involved in the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the treatment is established. \n\n\n\nThe story does note that the technique is new and was developed by one of the researchers.", "answer": 1}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that there is no clinically useful blood test to diagnose lung cancer currently available, and it implies the novelty of this test when it states that it builds on previous research. It also mentions that several other investigators are currently looking into blood tests for early-stage lung cancer.", "answer": 1}, {"article": "Get the facts.\nAnd, just like essentially every claim made by the anti-vaccination movement, these arguments are wrong.\nThis, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\nThat doesn\u2019t stop them from making them, or from them getting attention by mainstream media; attention they most assuredly do not deserve.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the study driving the coverage is \u201cnew,\u201d but beyond that doesn\u2019t establish what is different or interesting about this research compared with previous studies.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story establish the true novelty of the approach?", "explanation": "No claims of novelty were made.", "answer": 2}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\nMarch 11, 2010 (Miami Beach, Fla.) -- A moisturizing cream whose active ingredient is extract of onion can help take the redness out of new stretch marks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are many creams that combine moisturizers and plant extracts and claim to treat skin problems.\u00a0This story should have challenged the notion that adding\u00a0onion extract to a skin\u00a0cream makes it\u00a0in any way \"new.\" \u00a0\u00a0\u00a0", "answer": 0}, {"article": "Among the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\n\u201cIt is very important to keep in mind that multivitamin users tend be \u2018healthier\u2019 in general.\nShe concluded: \u201cThe question of whether multivitamins are good for you still remains!\u201d\nBut vitamin pills seemed to have less of an effect in women with heart disease, Dr. Susanne Rautiainen of the Karolinska Institutet in Stockholm, Sweden, and her colleagues found.\nSimilar studies have been done in men, with some confirming the current findings and others contradicting them, Rautiainen said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story accurately conveyed the lack of novelty of this treatment studied.", "answer": 1}]